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Introduction 
Obesity is vastly becoming of great concern in many areas around the world. In the 
United States alone 35.5% of adult men and 35.8% of adult women are classified as 
obese.1 Various physical, environmental, and behavioral factors can contribute to the 
onset of obesity in an individual’s life. In turn obesity can contribute to consequences 
including financial burdens, increased health risks such as diabetes, coronary heart 
disease, degenerative joint disease, certain types of cancer, as well as psychological 
issues.2 Obesity treatment can include lifestyle modification, pharmacological 
intervention, or surgery; however, better understanding of factors related to weight loss 
success and strategies for individualized effective treatment plans are needed. By 
identifying baseline factors that are associated with weight loss success there is potential 
for individuals to be better placed into the most appropriate individualized weight loss 
treatment plans, which may result in greater weight loss success.  
 
Part 1: Cause of Obesity 
Obesity is defined as having a body mass index (BMI) of greater than or equal to 30 
kg/m2.3, 4 This is caused by an imbalance of energy intake and energy expenditure leading 
to net energy storage.5 Information from the National Health and Nutrition Examination 
Survey (NHANES) suggests that there was an average daily intake increase from 1972 to 
2000 with 168 kcal a day for men and 335 kcal a day for women.6 This energy intake 
increase along with an estimated decrease in physical activity found by Church et al. of 
142 kcal per day decrease since 1960. This explains the increase in energy imbalance 
leading to weight gain over this period.6, 7 An increase in per capita energy intake over 
the past 40 years of a 20% increase reported by the USDA has changed the collective diet 
(figure 1).8, 9  
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Figure 1: Per capita energy intake according to the U.S. Department of Agriculture food 
disappearance data (corrected for waste). Daily energy intake has increase 20% from 
1970-2009.8, 9 
 
Energy expenditure occurs through resting metabolic rate, thermic effect of food, and 
physical activity.10 Resting metabolic rate is the amount of energy that is necessary to 
fuel the body at rest and is proportional to fat-free body mass. The thermic effect of food 
is the amount of energy the body uses to absorb and metabolize the food that is 
consumed. Physical activity accounts for the biggest portion of energy expenditure in an 
individual.10 Increased physical activity levels and frequency are associated with 
decreased risk of obesity.11 The body is also more prone to preserving existing body 
weight causing issues with weight loss in individuals who have already gained weight.10 
In situations of negative energy balance the body is more likely to defend against it, thus 
preserving current weight than it is for the body to defend against positive energy 
balance. Because so much of the population is already in a positive energy situation this 
can cause issues with correcting the positive energy state that would lead to successful 
weight loss.  
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A number of factors contribute to energy imbalance and need to be addressed in an 
individualized fashion including genetic, physiologic, environmental, psychological, 
social, and economic situation.12 Genetic predisposition of weight loss response may 
contribute to weight gain. This can be seen by the fact that there is large variability 
among individuals who are completing similar programs, suggesting that genetics plays a 
role in the response to the treatment and the amount of weight loss.13 Despite good 
adherence to a program, individuals may experience less than desirable results due to 
variations in the genes, both monogenic and polygenic. Monogenic obesity can be caused 
by variations in leptin and leptin receptor genes for example, however; these mutations 
are rare.14, 15 Polygenic obesity in due to gene-gene interactions, which causes a wide 
range of obesity characteristics that influence body fat accumulation and fat 
distribution.15 With variations in genotype obesity there is the need for different 
approaches utilized for weight loss, specifically addressing the mutations that are being 
expressed.15  
 
A patient’s physical abilities can greatly impact an individual’s ability to increase the 
physical activity portion of weight loss plans, thus potentially leading to greater weight 
gain and little to no weight maintenance. Behavioral factors, including eating patters, 
attitude towards food, willingness to make a change, and confidence in that ability to 
make a change can all contribute to overall weight loss success among individuals. If an 
individual is unwilling to make changes in their current behaviors there will be little 
likelihood of successful weight loss.  
 
Environmental factors can contribute to overall energy imbalance; this includes the 
“built” environment as well as medications that a patient may be taking. The built 
environment includes food availability, such as fast food options and healthy food 
availability in grocery stores and an environment structured so that individuals expend 
less energy in their daily activities of living. Regarding increased intake, factors that 
affect food choices, such as education level, income, and related socioeconomic variables 
need to be considered when addressing why there is an overall increased consumption of 
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calories.16 Another area that needs to be considered part of an individual’s environment 
includes the use of medications that cause weight gain. These drugs include psychotropic 
medications, some diabetic medications, anti-hypertensives, steroid hormones, and 
contraceptives.17 
 
Part 2: Implications of Obesity 
With an increase in the amount of individuals classified as obese there is an increase in 
the number of individuals who face the complications that are associated with obesity. 
Individuals with obesity have an increased risk of type 2 diabetes, coronary heart disease, 
some forms of cancer, osteoarthritis, nonalcoholic fatty liver disease, and high blood 
pressure.18 With an increase in the various diseases associated with obesity there is an 
overall decrease in the quality of life including depression, disability, physical 
discomfort, and possibly social isolation.18 Obesity is the second leading cause of 
preventable, premature death in the United States, second only to smoking with a 2 to 3 
times higher risk of death than those of normal weight.19, 20, 21 Of these deaths an average 
100,00 to 200,000 deaths are caused by the comorbidities that are associated with 
obesity.22 - 25 Individuals who are classified as obese are estimated to have a decreased 
life expectancy of 0.8 to 7 years.25, 26, 27  
 
Obesity contributes to the risk of serious health consequences. Obese women have a 10 to 
17-fold increase in risk for developing type 2 diabetes and obese men have an 11 to 23-
fold increase.28 Among these individuals a decrease in weight can significantly improve 
complications that are associated with type 2 diabetes including glycemic control, 
cardiovascular risk, and risk of some cancers.29 - 32 Along with diabetes, the presence of 
dyslipidemia is high among obese individuals. This includes elevated low-density 
lipoprotein cholesterol, decreased high-density lipoprotein cholesterol, and elevated 
triglycerides.32 This lipid profile is associated with increased risk of heart disease and 
stroke.18 Excess weight is also associated with nonalcoholic fatty liver disease, a chronic 
disease that may progress to end-stage liver disease.34 Obesity is also associated with 
increased risk of progression to end-stage renal disease.34, 35 
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In terms of mood disorders and obesity, it is unclear whether psychopathology is a cause 
or consequence of extreme obesity.36 Nonetheless, these issues can cause major problems 
in regards to successful weight loss and weight maintenance. Mood disorders are 
commonly seen among obese individuals.  Depressive disorder, dysthymia, and anxiety 
disorders have been diagnosed in up to 48% of candidates of bariatric surgery.37 - 43 Also, 
among these bariatric patients, around 25% report treatment from a mental health 
professional with 12% to 38% using psychiatric medication(s). Many of these 
medications are associated with excess weight gain and difficulty with weight loss.38, 40 - 
44 
 
Obesity, especially extreme obesity, is associated with reduced health-related quality of 
life.45 Investigators have found a positive relationship between BMI and physical 
limitations, bodily pain, and fatigue.46 - 51 Decreases in quality of life are associated with 
increases in anxiety, depression, feelings that food controls their life, and impaired social 
abilities.52 Many people feel that with an increase in weight there is an overall loss in the 
ability to control their lives, thus potentially leading to a further increase in weight due to 
the thoughts of them being out of control. Physical inabilities also contribute to overall 
decrease in quality of life, these issues can either be the cause of the increased weight 
gain or can be an effect of an overall increase of weight over time. Physical inability can 
lead to issues with everyday activities causing patients to be unable to complete daily 
tasks and physical activity. 
 
Part 3: Financial Impact of Obesity  
The financial impact of obesity is considered a huge burden to the United States health 
care system. Not only is there an increased cost associated with obesity itself, obesity 
related comorbidities need to be considered when calculating costs. The Center for 
Disease Control estimated that annual cost of obesity in the United States reached $147 
billion in 2008, with obese individuals having medical costs $1,429 higher than those of 
normal weight annually.19 Some studies have shown that with a decrease in obesity 
related comorbidities there will be an overall decrease in obesity related care and the 
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costs associated.53 In a matched cohort study carried out by Mason et al. looking at the 
same medical procedures between obese and non-obese individuals from 2005 to 2009 
there was over a $160 million difference in cost.53 This gap in costs was due to 
differences in utilization of hospital resources, differences in length of stay, and intensity 
of services. There is an increased association between obesity and an increased number of 
secondary and additional procedures needed by the patient including intubation, medical 
ventilation, physical therapy, and rehabilitation. It was concluded that because the 
patients were medically matched otherwise, that all differences in cost perioperatively 
were deemed due to excess body mass or its impact on postoperative demands.53  
 
Along with increased medical costs there are also costs associated with decreased 
productivity. This decrease in productivity is caused by higher rates of disease, disability, 
and death. Of the previously stated causes of decreased productivity, including disease 
and decreased quality of life, there is an estimated cost of $270 billion annually in the 
United States.54 Even a modest amount of weight loss can contribute to an increase in 
productivity and a decrease in general medical costs, thus leading to an overall decrease 
in the financial impact of obesity and its related comorbidities. 
 
Part 4: Understanding of Weight Loss  
4.1 Weight Loss and Weight Loss Success – Definitions 
When considering weight loss among obese individuals, the overall goal is to have a 
meaningful weight loss with prolonged maintenance of the decreased weight including a 
reduction in overall fat mass leading to a reduction of mortality and morbidity. A 
successful amount of weight loss is considered to be between 5% and 10% of baseline 
weight to see clinically significant improvements. With a weight loss of 5% to 10% there 
is a decreased risk of type 2 diabetes among high-risk individuals as well as a significant 
improvement in glycemic control among those with type 2 diabetes.21   
 
Typically, initial weight loss has a strong association with late and overall success of 
weight loss treatment.55 Individuals who had a weight loss of greater than or equal to 
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10% weight loss at the end of year one had a 10.4 times greater chance of sustaining 
greater than 10% weight loss at year four.56 However, successful weight loss and weight 
maintenance requires significant amounts of lifestyle modifications.57 Maintenance of the 
lost weight is associated with the initial weight loss, achievement of set goals, an active 
lifestyle, self-monitoring weight related behavior, a regular food intake pattern, and 
control over eating behaviors such as stress eating.58, 59 Overall, long-term success 
depends on the patient’s ability to incorporate large lifestyle and behavior changes.52 
Adherence of weight loss programs seems to be one of the most difficult aspects of 
successful weight loss.60 Increased frequency of face-to-face contact with patients over a 
long period of time helps direct adherence to changes, which later improves the outcome 
of the treatment.61 Web based interactions have not shown to be as beneficial as actual 
face-to-face encounters between a patient and a physician.30 However, different treatment 
approaches have varied definitions of weight loss success and varied amounts of patients 
reaching that successful benchmark complicating overall understanding of optimal 
approaches for weight management success.  
 
4.2 Health Benefits of Obesity Treatments 
Treatment of obesity is associated with many improvements in comorbidities and quality 
of life. In overweight and obese adults that are at high risk for type 2 diabetes weight loss 
of 2.5 kg to 5.5 kg can reduce the risk by 30% to 60%. In individuals with type 2 
diabetes, weight loss of 2% to 5% can result in modest reductions in fasting plasma 
glucose concentration and lower HbA1c by 0.2% to 0.3%. Weight loss of 5% to 10% can 
lower HbA1c levels by 0.6% to 1.0% and reduce the need for diabetes medications.62  
  
Individuals with elevated CVD risk that achieve 5% weight loss have an approximate 
reduction in 3 mm Hg systolic blood pressure and 2 mm Hg diastolic blood pressure. At a 
weight loss of greater than 5% there is an even greater reduction in blood pressure and a 
decrease in use of antihypertensive medications.62  
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Weight loss has a dose-response relationship with improvements in lipid profile. A 3 kg 
weight loss has been shown to have a mean reduction in triglycerides of at least 15 
mg/dL. A 5 kg to 8 kg weight loss was shown to have a reduction of LDL of 5 mg/dL and 
an increase in HDL of 2 to 3 mg/dL. Modest improvements in triglycerides, HDL, and 
LDL are observed with a weight loss of at least 3 kg.62 
 
Part 5: Introduction to Treatments 
Treatment for obesity can be carried out in a variety of different ways including 
pharmacology, surgery, lifestyle intervention, or any combination these.63 A 
comprehensive approach to weight management including diet, physical activity, and 
behavior therapy has been shown to be more successful than one intervention strategy 
alone.29 Treatment approaches should be selected based on the individual’s age, gender, 
degree of obesity, health risks, behavioral characteristics, as well as success of previous 
weight loss attempts.21  
 
Even a modest amount of weight loss of 5% to 10% of initial weight for an obese 
individual can create a great reduction in total cholesterol, low-density lipoproteins, 
cholesterol, and serum triglyceride levels and thus improving complications associated 
with obesity.21 These improvements lead to decreases in blood pressure and instances of 
insulin resistance, type 2 diabetes, and cardiovascular disease.21 Regardless of the type of 
treatment that is used on the patient, an overall decrease in weight creates an 
improvement of health status and quality of life.   
 
5.1 Pharmacotherapy 
In comparison to other diseases in which drugs are used for treatment, fewer options are 
available and approved for obesity.21 In order for a weight loss drug to be considered 
effective there needs to be a significant amount of absolute weight loss, percent of weight 
loss, and percent of patients achieving greater than or equal to 5% - 10% weight loss. 
There also needs to be a significant change in clinical measurements including blood 
pressure, glycemic control, and cholesterol compared to the placebo group.64 The FDA 
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must see meaningful weight loss if the drug meets at least one of the two guidance 
criteria. The first guidance criteria considers a drug effective if the mean weight loss 
between actual product and a placebo group must be at least 5% and the difference is 
statistically significant. The second considers a drug successful if the portion of subjects 
who lose ≥5% of baseline body weight in the treatment group is at least 35%, is 
approximately double the placebo group, and is statistically significant.65 As long as one 
of these criteria is met the FDA considers the drug to produce meaningful weight loss and 
will be approved for weight loss.  
 
For the most effective outcome while using medications, treatment should be paired with 
a lifestyle modification program as a drug treatment can only be maintained for a limited 
time.66 The benefits of pharmacotherapy cause it to a good resource for weight loss with 
significant decreases in blood pressure, lipid levels, and blood glucose levels with overall 
increases in insulin sensitivity.67 Current exploration of targeted pathways include 
medications that act centrally to suppress appetite and increase energy expenditure and 
medications that inhibit energy intake through the blocking of orexigenic signaling in the 
feeding center.21, 57 However, it remains unclear as to which type of medications pathway 
that is targeted is associated with the most significant and long-term weight loss.57  
 
There are risks that are associated with the use of weight loss medications and should be 
considered before putting a patient on these potent weight loss stimulators. This includes 
risk for development of a tolerance or the potential for addition, later leading to a change 
in medication therapy or potentially leading to a change in weight loss therapy all 
together. 
 
5.1.1 Currently Used Medications 
Monotherapy 
There are two main categories of weight loss medications that are approved in the United 
States. These include fat absorption inhibitors and anorexiants. Fat absorption inhibitors, 
such as lipase inhibitor medications, act peripherally to reduce absorption of dietary fat in 
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the gut.21, 63 Anorexins work to promote satiation, reducing the desire to eat. This is done 
through interfering with neurological pathways in the hypothalamus, by inhibiting 
orexigenic pathways (appetite stimulators) and promoting anorexigenic pathways.57  
 
Orlistat works peripherally as a lipase inhibitor, decreasing the amount of fat that is 
absorbed in the stomach and intestines from food by up to 30%.57, 68, 69 It is currently 
approved by the FDA for long-term weight loss.2, 65, 70 Orlistat can be found as an over 
the counter medication under the trade name of Alli or as a prescription under the trade 
name Xenical. The overall decrease in fat absorption contributes to the side effects of 
stearrhea and bowl incontinence with high fat meals.71 Orlistat contributes to weight loss 
leading to improvements in cardiovascular risk factors, type 2 diabetes, hypertension, and 
dyslipidemia. Orlistat therapy has been shown to increase the odds of ≥5% weight loss 
compared to diet only therapy after a 1-year follow-up.72  
 
Lorcaserin (Belviq) is a serotonin agonist causing anorectic effects leading to increased 
satiety and decreasing food intake causing to weight loss.73 The FDA approved it in June 
of 2012 to be used as a long-term weight loss drug for obese patients.74 Common side 
effects include headache, upper respiratory tract infection, nausea, and dizziness.75, 76 
Lorcaserin creates significant reductions in waist circumference and BMI as well as total 
cholesterol, LDL cholesterol, and triglycerides.76 Weight loss seen among lorcaserin 
users at one year showed a 4.5% to 5.8% decrease in baseline weight compared to the 
placebo group achieving 1.5% – 2.8% decrease in body weight.75, 77 
 
Phentermine, trade names Adipex-P and Suprenza, is a sympathomimemetic amine that 
acts as an appetite suppressant and energy expenditure promoter that is an approved 
short-term weight loss monotherapy by the FDA. Phentermine blocks the dopamine and 
norepinephrine transporters leading to an increase in dopamine and norepinephrine in the 
hypothalamus. This leads to reduced appetite and subsequent weight loss.68, 73 Studies 
have shown a 3.6 kg greater weight loss than those taking a placebo.69 It can lead to 
headaches, an increase in pulse rate and anxiety, an increase in blood pressure, and can 
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cause cardiovascular complications, especially in those that already have pre-existing 
cardiovascular conditions.73, 78 
 
Diethylpropion is an appetite suppressant, decreasing overall hunger sensation leading to 
weight loss, and energy expenditure promoter.63, 79 The appetite suppressant effect is 
cause by central nervous system stimulation, with mechanisms that are still uncertain.63 
Diethylprpropion, trade name Tenuate, is approved for short-term weight loss, but is 
currently being studied to see if it can be used for long-term weight loss. In a study 
carried out by Cercato et al. patients were placed on either diethylpropion or a placebo to 
see the effects of weight loss.80 Of the patients that were on the diethylpropion, 51.3% of 
them achieved 10% or more weight loss compared to 3.13% in the placebo group. When 
looking at the potential for using dietylpropion for long-term weight loss, at 6 months 
patients taking the drug lost an average of 9.8% of initial body weight, where the placebo 
group only lost 3.2%.80 Side effects that can be seen among individuals who are taking 
diethylpropion include tachycardia, elevated blood pressure, palpitations, and restlessness 
and anxiety.80 
 
Topiramate was originally used as an anticonvulsant and migraine prophylactic, but after 
significant weight loss was seen in epileptic patients it started to be used as a weight loss 
medication in obese individuals. Although, not approved specifically for weight loss by 
the FDA, it is used for short-term weight loss.4, 81 The mechanism by which topiramate 
works for weight loss is still unknown. It is speculated that it inhibits GABA actions and 
reduces excitatory glutamate actions.73 Side effects that can be seen with topiramate 
include paresthesia, fatigue, and difficulty with concentration.82, 83, 84 It is sometimes used 
as an adjunct to mood stabilizing drugs that have a tendency to cause patients to gain 
weight.73 Individuals on topiramate achieved greater amounts of 5% and 10% weight loss 
from baseline body weight than those on a placebo. Topiramate users exhibited 5.9% - 
6.5% weight loss compared to 1.9% weight loss shown in those on a placebo.83 
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Naltrexone and bupropion are also used as monotherapies for weight loss. Naltrexone is 
an opioid receptor antagonist used in the treatment of alcohol and opioid dependence, 
which also leads to suppressed food intake.85 Although not approved by the FDA for 
weight loss, naltrexone is being used off label for weight loss with varying success for 
significant weight loss.86, 87 Bupropion was originally used for depression and smoking 
cessation with mild weight loss seen as a side effect.88 Buproprion works by inhibiting 
norepinephrine and dopamine reuptake leading to suppressed appetite.73 However, 
cardiovascular concerns are still being assessed.89 
 
Combination Drugs  
Drugs are being used in combination when monothreapies do not seem to be effective for 
a patient. By creating combination therapies smaller doses of each medication can be 
used with synergistic effects allowing for multiple mechanisms to be utilized creating an 
overall greater amount weight loss. This includes the phentermine and topiramate 
combination called Qsymia, approved in 2012. Qsymia is thought to produce longer-
lasting weight loss results due to the synergistic effects.73 This combination can partially 
lead to a decrease in the side effects compared to either agent alone.90 - 93 
 
Another combination therapy, not yet approved by the FDA, is the mixture of naltrexone 
and bupropion known as Contrave. Contrave can lead to appetite suppression and 
subsequent weight loss.73, 94 The naltrexone that is added can remove the negative opioid 
feedback and enhance the effect of the bupropion.73 
 
5.1.2 Removed Drugs 
Although there are drugs that are available both in monotherapy and combination therapy 
there are many drugs that have been removed from the market for varying reasons. Fen-
Phen, a combination of fenfluramin and phentermine, is a serotoninergic combination 
that increases serotonin levels in the brain. Fen-Phen was removed from the market due 
to possible side effects of pulmonary hypertension and heart valve issues caused by 
fenfluramin.95 
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Recently, sibutramine, an FDA approved drug for long-term weight loss was voluntarily 
removed from the market. Sibutramine inhibited the reuptake of serotonin and 
norepinephrine in the central nervous system, thus increasing satiety, reducing hunger, 
and decreasing the drop in metabolic rate when weight was lost.95 Sibutramine stimulates 
the sympathetic nervous system, potentially causing issues with cardiovascular function 
including increased risk of heart attack and stroke.73 
 
5.2 Surgery 
Bariatric surgery has now become a viable option for weight loss in morbidly obese that 
have not responded to pharmaceutical and lifestyle modification options. Two major 
approaches are being utilized, these approaches include intestinal malabsorption and 
gastric restriction.96, 97, 98 However, due to surgical risks and complications, surgery is 
used selectively among individuals. Indications for consideration of surgery for obesity 
management include a BMI of greater than or equal to 40 kg/m2 or a BMI of 35 kg/m2 to 
39.9 kg/m2 with the presence of comorbidities, including type 2 diabetes, high blood 
pressure, and severe sleep apnea.18, 66 Although bariatric surgery is associated with an 
increase in success in terms of weight loss and improvements in comorbidities there are 
side effects that need to be addressed when discussing this option with patients.30, 99 Early 
complications occur in 5% to 10% of patients including pulmonary embolism, respiratory 
failure, stomal obstruction, bleeding, and gastrointestinal leaks.36 Many patients also 
experience later complications of nutrition and metabolic changes.  Occurrences of these 
complications vary between patients and are associated with the patient’s age, BMI, the 
type of surgery performed, and presence of other comorbidities.66, 100  
 
Bariatric surgery is associated with macronutrient and micronutrient deficiencies.101, 102, 
103 These complications are due to the surgical induced anatomical changes to the 
individual’s gastrointestinal tract and have been reported in at least 25% of patients.104, 105 
Macronutrient deficiencies include protein-calorie malnutrition and fat malabsorption.102 
Micronutrient deficiencies often include zinc, vitamin D3, folic acid, iron, and vitamin 
B12 . These deficiencies can be attributed to the change in the absorptive areas of the GI 
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tract, changes in co-factors (such as intrinsic factor) needed for absorption of certain 
micronutrients, as well as overall changes in dietary choices and decreased food intake.101 
For example, vitamin B12 is often deficient due to a loss of intrinsic factor, reducing the 
bioavailability, and also due to a decreased consumption of B12 containing foods like 
meat.106, 107 A vitamin D deficiency can potentially cause hyperparathyroidism leading to 
bone disease, muscle weakness, and cardiovascular issues in high-risk individuals.108 
Patients that receive weight loss surgery should be taught potential issues with macro and 
micronutrient deficiencies and also be monitored to avoid potential side effects that 
accompany the deficiencies. Supplementation based on the patient’s history and type of 
surgery performed can be prescribed and often times can prevent a patient from getting a 
deficiency.102 Macronutrient and micronutrient deficiencies can also be do to a large 
number of individuals experiencing vomiting and gastric dumping. This has been 
reported in one-third to two-thirds of all gastric bypass patients.46, 110, 109 Often times this 
is the result of overeating or consuming foods that are not recommended post surgery, 
such as foods high in sugar.45 
  
Along with micronutrient and micronutrient deficiencies, there can be difficulty with 
compliance pre- and post bariatric surgery. Issues including missed appointments, binge 
eating, and depression, which are associated with poorer weight loss. This supports the 
current clinical practice of having regular contact between the physician and the patient 
as well as having aggressive treatment plans to address psychological symptoms and 
maladaptive eating patterns both before and after surgery.61 By addressing issues prior to 
bariatric surgery there is the possibility of decreasing the likelihood of poorer weight loss. 
Strong associations between binge eating and poor weight loss in bariatric patients have 
been shown by multiple studies.46, 61, 111 Issues with disordered eating may continue post 
surgery if not addressed and corrected.36, 46, 111 With greater understanding by the patient 
of what it means to have weight loss surgery and what the expectations are as a patient 
there can be a more successful outcome.61  
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5.2.1 Restrictive 
Laparoscopic adjustable gastric banding (LAP-BAND) is a laparoscopic technique used 
to separate the stomach into two pouches. This is done by placing an adjustable band 
around the stomach, just below the gastroesophageal junction, that can be inflated to 
allow for a varying sized channel between the two pouches.112 This procedure is 
associated with slow/steady weight loss and results in approximately 25% excess weight 
loss at 5 years in two-thirds of the patient population.113 Adjustments to the band may be 
necessary to increase or decrease the passage size between the two sections of the 
stomach, with an increase in inflation leading to a decrease in oral intake.112 LAP-BAND 
has the lowest risk of complications compared to gastric bypass, sleeve gastrectomy, and 
duodenal switch.114 However, re-operations vary enormously within patients from 2% to 
80%.115 Some patients may experience prolapse, usually of the anterior stomach, with 
urgency of reparative surgery dependent on the patient’s symptoms.112 Patient’s 
complications and symptoms are not exhibited the same by everyone; therefore, patients 
are recommended to undergo an annual esophagram to check for complications.112  
 
Sleeve gastrectomy (SG) is an irreversible procedure reducing the size of the stomach to 
a narrow gastric tube. The sleeve gastrectomy procedure has gained in popularity and is 
no longer just used in high-risk or super-obese patients as the first step of a two-part 
approach.116 - 120 SG procedures have shown both short and intermediate positive results 
and do not seem to have as many nutritional deficiencies as gastric bypass.121 - 125 As with 
gastric bypass, SG is associated with safe and effective reduction in comorbidities, but 
without the high need of supplementations that are needed with gastric bypass.122 Weight 
loss at 5 year follow up has been reported at 55% loss of excess body weight with greater 
than 50% excess weight loss sustained after 5 years.126, 127 However, major complications 
of the gastric sleeve procedure include leakages in the lines (1.2%) as well as internal 
bleeding (3.6%); however, risk outcomes still differ between studies.121 – 123, 127 - 129 
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5.2.2 Malabsorptive 
Biliopancreatic diversion with duodenal switch consists of removing a large portion of 
the stomach and attaching the duodenum to end of the intestine, closing off the middle 
portion. This leads to a decreased stomach and intestine size limiting the time that 
digestive enzymes can interact with food, decreasing in the absorptive area for calories 
and nutrients.18 Originally just the biliopancreative diversion, the addition of the 
duodenal switch eliminated negative side effects. Biliopancreatic diversion with duodenal 
switch has been shown to provide the greatest sustained weight loss among all bariatric 
procedures.130 Depending on the amount of the intestine that is left connecting the 
stomach and the colon, it has been reported that excess weight loss was between 70% and 
80%.130 With a smaller portion of the intestine available for the digestion and absorption 
of nutrients, the biliopancreatic diversion with duodenal switch has the greatest number 
of nutritional deficiencies leading to the requirement of long-term follow-up care.130  
 
5.2.3 Restrictive and Malabsorptive 
Roux-en-Y gastric bypass surgery was the most commonly used weight loss surgery as of 
2011.114, 131, 132 Massive weight loss is seen in patients who receive this procedure. 
Reductions in obesity-related comorbidities and mortality occur with randomized 
prospective trials reporting 50% to 80% loss of excess body weight over 5 years.57, 130, 133 
- 136 In gastric bypass a small pouch is created at the top of the stomach, the small 
intestine is then connected to the pouch to bypass most of the stomach and creating a 
distal remnant.57, 137 This creates a large shift in the volume of food that is consumed, 
thus leading to decreased weight through decreased food intake.137 The newly formed 
pouch is reduced to roughly 5% of the original capacity of the stomach.57 However, with 
a decrease in the stomach size and intestinal absorptive surface there are issues with 
nutrient absorption such as iron, calcium, thiamine, and vitamin B12.57, 122, 137 
Postoperative complications like deep vein thrombosis, anastomotic leaks, internal 
hernias, gastrointestinal bleeding, wound complications, and staple-line disruption have 
been seen in 10% of cases.138, 139, 140 Although gastric bypass is associated malabsorption, 
it has shown to have good long-term results with successful weight loss, some important 
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improvements in health outcomes, and improved quality of life.109, 141 - 143 Most patients 
exhibit sustained weight loss and resolution of comorbidities within the first 2 years after 
surgery with long-term studies showing weight regain after 10 to 15 years of surgery.114, 
144 - 147  Studies have reported that most weight regain beginning after 2 years 
postoperatively and is estimated at around 15% of the maximum weight loss seen.104, 140, 
148  
 
Although there are complications with bariatric surgery, this treatment has become more 
common with the use of laparoscopic techniques.132 Surgical treatment is associated with 
substantial weight loss leading to improvements in obesity related diseases like diabetes, 
hypertension, dyslipidemia, obstructive sleep apnea, and quality of life.29, 143, 149, 150 
Bariatric surgery is considered the most effective treatment for morbidly obese 
individuals, but it like all other therapies is only part of the tools needed.146 Important 
underlying issues still need to be addressed when trying to achieve weight loss success. 
 
5.3 Lifestyle Intervention 
Lifestyle intervention can include behavioral strategies, diet modification, and exercise 
modifications. By addressing issues within an individual’s lifestyle long-term changes 
can be made leading to initial weight loss success and sustained weight maintenance. 
Successful lifestyle interventions are associated with an individual’s higher self-efficacy, 
higher self-esteem and motivation, and realistic goals for weight loss and weight 
expectations at baseline.55, 151, 152 Lifestyle intervention includes a moderately reduced 
calorie diet, increased physical activity, and behavior intervention to facilitate 
adherence.29  
 
Caloric restriction is commonly the foundation of most weight loss programs.57 A general 
guideline of caloric deficit of 500 to 1,000 kcal of estimated energy requirements should 
result in a weight loss of 1 to 2 pounds per week.29 Behavior intervention includes the 
incorporation of nutrition education, such as reading nutrition labels, recipe 
modifications, and cooking classes. By increasing an individual’s knowledge there is a 
  19 
chance at changing the patient’s food choices.29 Behavioral modification has been shown 
to be effective in decreasing body weight; however, there is a need for this type of 
intervention to be intensive and sustained.36, 153 - 155 In a study carried out by Kong et al. 
intensive lifestyle intervention were assigned to individuals with varied level of 
confidence in their ability to make a change.156 Participants with an increased level of 
confidence regarding capability to increase level of physical activity demonstrated a 
significant percentage of weight loss at one year. With the significant weight loss there 
was better prevention of the development of obesity related health issues including type 2 
diabetes and cardiovascular events during follow-up of these study participants.156   
 
Studies continue to show that physical activity should be combined with caloric 
restriction in order to maximize weight loss among individuals. Not only can exercise 
contribute to an increase in the amount of energy that is expended by an individual, it 
also improves metabolic fitness, even if there is little weight loss achieved.157, 158, 159 
Recommendations for physical activity include 30 minutes of moderate to vigorous 
physical activity 5 to 7 days per week.57 An increase in physical activity contributes to 
weight loss, may decrease highly concerning abdominal fat, and may help with 
maintenance of weight after initial weight loss is successful.29 Aerobic activity 
significantly increases energy expenditure, improves cardiovascular function, and 
increases metabolic fitness.160 Strength training promotes lean muscle mass, maintains 
resting metabolic rate as well as improving muscle strength and endurance, thus 
supporting further increases in physical activity.161, 162 
 
Typically, intensive interventions only addressing lifestyle changes have a high drop out 
and non-responder rate.156 This suggests that not all patients are suitable for lifestyle 
changes alone. Therapy escalates to include pharmacotherapy and surgery where 
appropriate, with specific choices made after individualized, detailed assessment. Other 
studies have suggested that patients tend to struggle to adhere to low-calorie diets and 
thus over time the caloric intake increases significantly, especially in individuals who 
receive bariatric treatments.36, 114, 148, 163  
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5.4 Combination Treatments 
By combining various treatment approaches a greater weight loss and longer weight 
maintenance can be obtained leading to an overall improvement in life. Comprehensive 
weight management programs are more successful than using any one intervention 
alone.29 Addressing multiple areas of concern may allow for the patient to achieve weight 
maintenance over a longer period of time, contributing to a greater improvement of 
health. Treatments should last at least 6 months with increase in length depending on the 
weight loss that is achieved with follow–ups to provide successful weight management 
approaches.29 
 
Comprehensive weight management programs can lead to increased weight loss by 
incorporating multiple areas. This could include various aspects of behavior therapy such 
as self-monitoring, stress management, stimulus control, problem solving, and social 
support. When combining this with diet and physical activity higher weight loss can be 
seen.29 By combining different approaches there are multiple synergistic ways in which 
energy intake can be decreased and energy output increased.  
 
For individuals who have failed with other approaches, surgical procedures could 
promote significant weight loss and improve comorbidities; however, behavior 
interventions should be used in combination to prevent lapses in corrected eating 
patterns.57 Along with increased weight loss, behavior modification strategies need to be 
implemented to decrease the chance of unwanted side effects, such as dumping 
syndrome, when eating the wrong diet after bariatric surgery.36  
 
Part 6: Barriers to Weight Loss Success 
Although many treatment types are available, there are many factors that contribute to the 
issues that are seen by many patients trying to reach a successful weight loss goal.  One 
major barrier to weight loss includes the generalized weight loss plans that are 
administered to patients seeking help. This generalized approach does not address an 
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individual’s gender, age, or socioeconomic status for example, causing treatments to be 
unsuccessful potentially leading to a decrease in compliance. This also correlates with the 
number of visits that an individual will attend, which is also associated with success in 
weight loss. A greater number of visits predicted more successful maintenance of weight 
loss, with 10% weight loss maintainers having significantly more treatment contacts than 
patients who maintained a loss of 0 – 4.9% or who gained back above baseline weight.56 
By not addressing these factors there may be unrealistic goals set by the physician and 
patient and a decrease in the amount of visits later contributing to overall decreased 
likelihood of success.29 
 
Another barrier to weight loss success is individual variability in readiness to change, 
confidence in ability to make a chance, and sustained adherence. Exhibiting low 
readiness to change can potentially affect the change of success, creating more drastic 
need for various treatment types.58 In bariatric patients, it has been noted that 
preoperative behavioral complications may impair postoperative weight loss and long-
term weight maintenance.36 A decrease in adherence of changes that are prescribed 
contributes to an overall lack of ability to achieve weight loss goals. If an individual is 
unable to change their behavior and effectively implement change in areas including 
dietary barriers, like eating away from home too often, eating high caloric foods, and not 
paying attention to diet, there is an overall decrease odds of being successful in weight 
loss by 48% to 64%.58 This suggests that there may need to be more focus on behavior 
changes that are done in order to achieve moderate weight loss and maintain that body 
weight even in surgical patients.  
 
Other contributing barriers include medical factors preventing weight loss. This includes 
medications, physical abilities, and other health issues that may be present that prevent 
lifestyle change or increase in physical activity. With a wide range of medications that 
cause weight gain among individuals, it is hard to determine what factors of the 
medication are causing the weight gain. However, there is evidence that some of the most 
prescribed drug classes do cause significant weight gain.164 Decreased energy 
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expenditure, due to decreased physical ability can cause issues with weight gain and 
overall decrease in quality of life.164 
 
Another barrier to consider in terms of weight loss success is the issue of perceived 
barriers, which can include time to exercise, cost of healthy foods, and social support.58 
According to Elfhag and Rossner, both pressure and lack of social support are important 
in weight loss with ability to handle life stress and having better coping strategies being 
associated with successful weight maintenance.55 If these perceived barriers are not 
addressed when prescribing a weight management plan, there is a greater chance of 
unsuccessful weight loss and decreased compliance. 
 
Part 7: Determining the Best Treatment 
Determining the best treatment for an individual undergoing treatment for obesity can be 
complicated. History of weight cycling, disinhibited eating, binge eating, hunger or 
eating in response to negative emotions and stress are factors that can contribute to 
development of obesity and difficulty with achievement and maintenance of weight loss. 
Without proper treatment and follow-up the instance of weight regain is highly prevalent. 
Obese individuals typically regain about 1/3 of the lost weight within the first year.56 By 
identifying key areas in which an individual may struggle, there is the potential to prevent 
the individual from weight regain and aid in success of weight loss. Barriers including 
medical history, previous weight loss attempts, motivation and willingness to change, and 
ability to set goals for one’s self are associated with weight loss success.55, 156, 165, 166  
 
The prevention and treatment of obesity will be better achieved by targeting existing 
effective interventions specific to each patient.156 By addressing factors associated with 
barriers of weight loss success there can be an overall understanding of what needs to be 
changed, what it will take to make those changes, and establishing successful goals. By 
addressing these areas there can be greater success not only in the weight loss that is 
seen, but also the chance of return visits and completion of weight loss programs. With 
the wide variety of patients that are being seen at weight management clinics, there needs 
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to be some understanding of the differences between patients and application of this 
understanding to the individual needs of each patient.   
 
Part 8: Baseline Predictors of Success 
Identifying an individual’s characteristics that might predict how well they are able to 
respond to treatments could lead to improved success and reduce weight regain.55 These 
factors can also contribute to the type of treatment that an individual is placed on, 
decreasing the chance of an individual spending time on a treatment that doesn’t end up 
benefiting them. By placing a patient on the correct treatment right away there is a greater 
chance for immediate success, which later leads to an overall higher success in long term 
weight loss.55 Weight loss within the first year has been shown to increase the odds of 
achieving a >10% weight loss after 4 years by 10.4 times more than those who lost <5% 
in the first year.56 It is important to identify factors that could potentially cause issues 
with weight loss due to the already difficult nature of weight loss and weight 
maintenance.58 There is potential for factors related to medical reasons (controlling blood 
sugar or acid reflux), disordered eating patterns, socioeconomic status and food 
insecurity, changes in hunger perception, emotional eating, binge eating, and potentially 
issues with craving driven eating to cause issues with weight loss. Slight increases in 
consumption due to any type of factor can lead to an overall increase in weight and 
difficulties with weight loss. 
 
8.1 Preventative Medical Eating 
Medical reasons that can contribute to subsequent weight gain include eating to correct or 
prevent low blood sugar or eating to reduce stomach acid or pain. Many patients 
experience weight gain and increased fat mass while undergoing diabetes treatment with 
insulin.167 An increased intake of food during the day can lead to an overall increase in 
calorie intake. Hypoglycemic episodes are treated with varying amounts of glucose or 
glucose containing foods.168 Depending on the amount of occurrences of hypoglycemia 
an individual has, there is the potential for large amounts of calories to be consumed over 
time, contributing to excess weight. Addressing these issues with behavioral and diet 
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modification can lead to an overall better control of blood glucose and gastrointestinal 
reflux disease symptoms leading to a decreased need to snack to control these issues.  
 
8.2 Disordered Eating Patterns 
Changes in what is considered normal eating patterns can be classified as having 
disordered eating patterns. Disordered eating patterns includes frequency of eating, 
preparation of foods, and conditions of where the meals are consumed. All of these 
aspects can contribute to a potential positive caloric consumption leading to greater 
weight gain as well as issues with sustained weight loss.  
 
Increasing the frequency of meals consumed can contribute a significant increase in 
caloric intake if calories are not cut throughout other parts of the day.169 This includes 
increases in snack consumption, especially if the snack that is consumed in a non-hungry 
state due to the nature of snacks being high-energy and low satiety.170  
Along with increased frequency of eating, issues with increased portion sizes are 
contributing to higher caloric consumption.16, 170 An increase in portion sizes as well as a 
decrease in food quality has led to increased energy density and increased energy intake 
throughout the day.171, 172  
 
Preparation of meals as well as conditions in which meals are consumed is contributing to 
increases in consumption as well as increases in energy density of the foods that are 
being consumed. An increase in the amount of people that are eating away from home at 
fast-food restaurants and sit-down establishments has shown an increase in overall weight 
gain among individuals. Fast food consumption has increased from 2% to 28% of total 
food spending over the past 50 years.173 The quick nature of the meals that are provided, 
the palatability, as well as the cheap cost has caused individuals to feel that these options 
are best for their current lifestyle. The prevalence of food that has very little prep time 
have also shown to be increasing, causing an increased consumption of salt, fat, and 
calories.173  
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A change in eating environments has also contributed to a higher amount of calories that 
are consumed. Eating in front of the TV or computer can cause an individual to not 
realize how much food they are consuming. This causes them to over consume when 
normally they would have hunger cues to get them to stop eating.8 Also, a shift in the 
meal patterns, including skipping meals such as breakfast has been associated with 
increased weight gain.170 The prevalence of skipping breakfast has increased over past 
decades, contributing to the increased weight gain and other adverse health outcomes.174  
 
8.3 Food Insecurity 
Socioeconomic factors that contribute to potential weight gain encompasses concerns 
about not having enough food to eat, not having enough money to consume a healthy 
diet, and frequency of visiting a food pantry. Obesity is disproportionately associated 
with individuals of low economic status with the prevalence of obesity rising among 
those of low socioeconomic status. Two potential mechanisms may be contributing to 
this occurrence.175 First, the idea that individuals who are food insecure are overweight 
because they can only afford cheaper food, which tends to be more calorie dense leading 
to excessive energy intake.176, 177 Second, those individuals who are food insecure go 
through periods without sufficient food leading to the tendency to overeat when sufficient 
food is available, contributing to overall increased energy intake.178, 179 Current evidence 
suggests that mildly food-insecure individuals are most likely to be overweight and obese 
in both men and women, with stronger associations seen in women.180, 181, 182  
 
8.4 Decreased Hunger Perception 
Changes in hunger perception can increase an individual’s feeling of hunger when 
normally they would have decreased hunger cues after eating. Hunger perception 
involves multiple factors that influence the hunger cues that are present within brain 
including cues from the central nervous system (CNS) and body fat mass.16  
 
Satiation and satiety are used to describe perception of fullness and reduced interest in 
food after a meal, respectively.16 A change in the body’s understanding of satiation and 
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satiety can cause an issue with excess eating during a meal from not being able to 
interpret the signals for satiation. Normally these responses allow for termination of 
eating before reaching the gastric capacity so an appropriate amount of time is available 
for the body to be able to digest and distribute nutrients throughout the body.183 This 
effect is caused by a combination of gastric distention and the release of peptide signals 
from the gastrointestinal tract.184 Normally gastric distention is sensed by 
mechanoreceptors in the stomach, which then relays a signal through the vagal afferent 
and spinal sensory nerves to the hindbrain.185 Some peptides released from the 
gastrointestinal tract that cause satiation and satiety include cholecystokinin (CCK), 
glucagon-like peptide-1 (GLP-1), oxyntomodulin, peptide YY, apolipoprotein A-IV, and 
enterostatin.185 The pancreas also releases peptides to induce satiety, these include 
pancreatic polypeptide, glucagon, and amyline.16, 186, 187, 188   
 
Leptin, a hormone released by adipocytes, plays an important role in energy homeostasis 
by signaling to the brain changes in energy balance and fuel storage.16, 189, 190 Leptin is 
present in the body in relation to the amount of fat mass present in the body and acts on 
the brain as a negative feedback regulator by restraining energy intake.190 A decrease in 
leptin signaling causes an increase in food intake, positive energy balance, and fat 
accumulation.16, 189, 190 Leptin acts on and promotes neurons that express 
proopiomelanocortin (POMC) synthesis and releases melanocortin peptides potentially 
causing anorexigenic effects on the body.190  
 
8.5 Emotional Eating  
Emotional eating can include excess consumption when in a depressed, stressed, or bored 
state, as well as using food as a reward. Emotional eating is associated with higher 
consumption of snacks, potentially adding a significant amount of calories during the 
day.191 Emotional eating is involved with weight gain as it is often linked with poor diet, 
including greater intake of energy-dense foods such as high-fat snacks.192 When patients 
are able to restrain their eating patterns and decrease their levels of uncontrolled 
emotional and binge eating there is a greater chance of weight loss and maintenance.193 
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Although no exact estimates for emotional eating prevalence have been measured, there 
is evidence that it is more common among obese individuals than normal weight 
individuals.194 This difference could be due to the fact that obese individuals show greater 
responses in brain reward regions to high fat and high sugar foods.195, 196, 197 Adults with 
greater reward center activation show poorer response to weight loss treatments.198  
 
8.6 Binge Eating  
The prevalence of binge eating disorder occurs in 3.5% of women and 2% of men 
totaling 3% of the population.199, 200 Of the individuals who have binge eating disorder, 
60% of them are obese and have ongoing weight gain.201 Binge eating includes hiding 
food consumption, having issues with stopping eating, and a feeling of being out of 
control when eating with the potential for eating until becoming uncomfortably full. 
Binge eating is associated with higher weight, more weight regain and issues with weight 
cycling after weight loss.202, 203 It is also considered to be a barrier to weight loss success 
with eating behavior being an important role in the prevention of obesity.203, 204, 205 Binge 
eating can also be associated with the feeling of guilt, shame, and disgust after eating.199 
By identifying binge eating in the beginning stages of weight loss and subsequent weight 
maintenance there is the possibility for prevention of failure in weight loss.193 In 
particular, individuals who exhibit binge eating disorder that have received Roux-en-Y 
gastric bypass showed significantly lower excess weight loss than those that do not 
exhibit binge eating at two year follow up (figure 2) .206 Although this significance was 
not seen right away (6 months follow-up), the occurrence of binge eating during longer 
follow up shows significant issues within the ability of an individual with untreated binge 
eating disorder to sustain the weight loss.206 
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Figure 2: Significantly higher percent excess BMI loss at year 2 in non-binge eating 
individuals than binge eating individuals post Roux-en-Y gastric bypass.206 
 
The presence of disinhibited eating, or the tendency to overeat in the presence of food, 
and lack of dietary restraint seem to impact individual’s weight significantly and are 
associated with weight gain and higher body weight.204, 207 In a study carried out on 
women aged 55 – 65, disinhibited eating was a significant independent predictor of 
weight change. Similarly, women with a high level of disinhibited eating as well as high 
levels of restraint had lower weight than women with high levels of disinhibited eating 
with low levels of restraint.204 By addressing issues with disinhibited eating when 
restrained eating is not present there will be a positive association with weight loss.204 
This data contributes to previous research that eating behavior is an important factor in 
determining excess weight gain in adulthood. 
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8.7 Craving Driven Eating 
Food cravings issues include always thinking about food and eating, giving into thoughts 
about food and eating, and as with emotional eating, eating can occur when not hungry. 
The association between food cravings and the occurrence of obesity has become more 
important due to the dramatic growth of obesity and the occurrence of food cravings.208, 
209 Cravings, which arise with hedonic or pleasure and driven habit pattern formation, 
have been shown to lead to obsessive thoughts about food and impulsive consumption of 
craved foods in some individuals increasing the risk for weight gain.210 Thus, food 
cravings have the potential to be used as a predictive factor of future high caloric food 
intake and subsequent weight gain among individuals.211  
 
There is, however, variability in the occurrence and strength of the food cravings among 
individuals. Women who reported having either binge eating disorder or nighttime eating 
syndrome were more likely to have higher levels of food cravings than those who did 
not.212 Patients seeking bariatric treatment also have greater occurrence of food cravings, 
especially related preoccupations with food.213 By better understanding the nature of the 
food cravings for bariatric patients, there is potential to improve outcomes following 
surgery post-operatively as well as earlier intervention pre-operatively.213 
 
Along with initial weight loss, individuals who have regained weight have less of an 
ability to cope with food cravings.214 Overall food cravings have been related to high 
BMI, dropout from weight loss treatments, and an increased number of lifetime weight 
loss attempts.209, 215 Therefore, potentially leading to an overall decrease in successful 
long-term weight loss, weight maintenance, and lifestyle changes. 
 
With the high prevalence of obesity and obesity related comorbidities, individualized 
treatment approaches that will allow for the greatest amount of successful weight loss for 
each patient need to be designed. Treatment approaches that are currently in place include 
pharmacotherapy, weight loss surgery, and lifestyle modification. Although there are 
multiple treatment choices for someone looking to lose a significant amount of weight, 
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the practice of generalized treatment strategies contribute to lower weight loss success 
and greater weight regain recidivism. The barriers that are currently exhibited by patients 
need to be addressed in order to achieve successful and meaningful weight loss.  
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Chapter 2: Baseline Traits as Predictors 
of Success in Medical Weight 
Management 
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Study Review 
Background: Although there are current treatment plans for individuals who are seeking 
to lose a significant amount of weight, success rate are highly variable. Barriers to 
success include lack of attention to development of individualized weight loss plans, 
issues with lack of readiness to change or confidence to make a change, and pre-existing 
medical conditions and medications that inhibit weight loss. By understanding and 
addressing an individual’s baseline characteristics there is the potential to create a more 
successful individualized weight loss program.  
 
Aim: To determine the relationship between baseline characteristics and subsequent 
weight loss in individuals at the University of Minnesota Adult Medical Weight 
Management clinic (MWM clinic).  
 
Materials/Subjects and Methods: Three-hundred fifty intake assessment forms from the 
MWM clinic were collected over a one and a half year time frame. Assessments were 
checked for completion based on answers of the Eating Habit (Table 1) and Eating Habit 
Frequency sections (Table 2), excluding any patient from further analysis if either section 
was not completed. The questions were split into 6 trait categories including preventive 
medical eating, disordered eating patterns, food insecurity, hunger disorder, emotional 
eating, and craving and binging. Later, craving and binging were split into binge eating 
and craving driven eating to determine the relationship between binging and craving. 
Data from a total of 219 patients were used for statistical analysis using SAS (version 9.3, 
SAS Institute Inc., Cary, NC).  
 
Results: Mean months of follow-up time for individuals with at least two visits (n = 84) 
was 4.05 ± 2.93 with significant difference seen between men (3.66 ± 1.95) and women 
(4.24 ± 3.29) (P = 0.040). Mean weight change per 30 days was -2.62 ± 4.05         
(female: -2.13 ± 3.47; male: -3.65 ± 4.99) and the mean percent weight change per 30 
days was -0.96 ± 1.46 (female: -0.82 ± 1.40; male: -1.26 ± 1.56). Success of 5% baseline 
body weight was seen in 42 (50%) and 10% in 23 (27%) of the population. Significant 
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difference was seen between individuals who reported food insecurity compared to those 
who did not with change in weight per 30 days with individuals reporting food insecurity 
having a change in weight of -1.2 ± 0.8 pounds and those not reporting food insecurity 
having a change in weight of -3.5 ± 0.5 (P = 0.017). Percent change in weight per 30 days 
was seen to be significant between individuals with food insecurity (-0.36 ± 0.3) and 
those who did not report food insecurity (-1.3 ± 0.2) (P = 0.008). Highest odds ratios 
were seen in individual reporting food insecurity versus not and those reporting craving 
and binging versus not. Individuals who did not report food insecurity were 4.1 times 
more likely to reach 5% success (P = 0.010) and 5.6 times more likely to reach 10% 
success (P = 0.955). Patients that did not report craving and binging were 2.2 times more 
likely to reach 5% success (P = 0.306), and 3.7 times more likely to reach 10% success  
(P = 0.072).  
 
Conclusions: Individuals who self-reported food insecurity had significantly less weight 
loss per 30 days and percent weight change per 30 days compared to those who did not 
report food insecurity. Disordered eating (87%), craving driven eating (71%), and binge 
eating (82%) were the most common baseline traits seen in our patients. Women reported 
emotional eating more frequently than men (women: n = 42 (74%); men: n =14 (52%);   
P = 0.047). Hunger disorder was only reported in 59% (36 women and 14 men) of our 
study patients and was not statistically different between men and women. Presence of 
craving and binging was seen in 77% of females (n = 40) and 61% of males (n = 14)       
(P = 0.153).  
 
In conclusion, hunger driven eating was not as strongly reported in our obese population 
as some non-hunger related baseline traits including emotional eating and binging and 
craving driven eating. Food insecurity was negatively related to weight loss success, 
suggesting that low socioeconomic status remains a major barrier to successful weight 
loss. 
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Introduction 
Obesity and its related comorbidities are a significant public health issue within the 
United States and around the world.1 Contributing to the onset of obesity are physical, 
environmental, and behavioral factors that lead to increased energy input and decreased 
energy output. These factors interact to create an imbalance between energy intake and 
energy output leading to overall excess weight. With excess weight gain and decreased 
quality of life there is an increased risk of type 2 diabetes, coronary heart disease, some 
forms of cancer, and high blood pressure.18  
 
Prior weight loss treatments have yielded highly variable amounts of success among 
individuals. Although weight loss success is defined in a number of ways, most people 
consider a loss of 5% to 10% of baseline weight to be beneficial for individuals.29 
Treatment approaches that are being used include pharmacotherapy, weight loss surgery, 
and lifestyle modification. However, there are many barriers that should be addressed in 
order to obtain the greatest amount of weight loss.  
 
Identifying key information within a patient’s history including attitude, eating habits, 
comorbidities, and medications can potentially lead to more successful outcomes. These 
baseline predictors could be utilized to design individualized treatment plans that would 
be more successful and lead to less variability of success among obese individuals. 
Baseline predictors include preventive medical eating, disordered eating patterns, 
socioeconomic status and food insecurity, changes in hunger perception, emotional 
eating, binge eating, and craving driven eating. By addressing these issues specific to the 
patient who is being treated, there is a greater chance of successful and sustained weight 
loss. 
 
Part 1: Project Objectives 
Based on the ever-increasing need for successful treatments for obese individuals, the 
research objectives were designed to better understand the patient population at the 
University of Minnesota Adult Medical Weight Management clinic (MWM clinic). 
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Along with demographic information, intake assessments were used to determine if there 
are any predictors of success based on baseline traits. Based on the self-reported answers 
on the intake assessment categories, describing individuals’ eating habits and frequencies, 
provides information that not only would be helpful in creating an individualized weight 
loss plan, but might also predict how successful they would be.  
 
Based on the descriptive categories that were created and then used to group questions, 
the research hypothesis was that individuals who have higher occurrence of preventive 
medical eating, disordered eating, food insecurity, hunger disorder, emotional eating, 
craving and/or binging driven eating would exhibit less weight loss than those who did 
not identify those baseline traits. Namely, individuals who only lacked nutritional 
knowledge needed for successful weight loss. Further, we sought to characterize which of 
these additional factor(s) were the most significant hindrances to successful weight loss 
in our patients. 
 
We additionally sought to further examine data from subjects who exhibited binge and 
craving driven eating patterns. It was hypothesized that the individuals who identified as 
bingers were a subset of individuals who identified as cravers. Groupings of questions 
were used to identify baseline traits that potentially predict successful outcome of weight 
loss. 
 
Part 2: Materials and Methods 
2.1 University of Minnesota Medical Weight Management 
The University of Minnesota Adult Medical Weight Management clinic (MWM clinic) 
uses an intake assessment for their patient population to deliver individualized treatment 
plans for the management of excess body weight. By identifying demographic 
information, previous weight loss attempts, medical history, eating habits, and behavior 
and attitude toward change the physicians at the MWM clinic develop plans that are 
tailored to the individual and their situation. Each new patient to the clinic completes the 
intake assessment prior to or during the initial appointment. The answers to the 
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assessment are reviewed and discussed by the physician and patient who work together to 
design a weight loss plan.  
 
2.2 Data Extraction  
Data covering a two and a half year time period from 3/1/2010 to 9/10/2012 were 
extracted from Allscripts and EpicCare to create the Access (2013, Microsoft 
Corporation) database utilized for this analysis. Information that was extracted included 
patient’s demographic information, clinic encounters, anthropometrics, medications, 
medical problem history, laboratory orders, and any prior bariatric surgical procedures. 
The total population included 1,174 patients that would be later used in conjunction with 
the baseline intake assessment forms to determine eligibility for the current analysis. 
Patient baseline intake assessment forms were matched based on first and last name and 
date of birth against the overall population to pull in all previous medical history from the 
overall clinical database for subjects in this analysis. 
 
2.3 Intake Assessment  
2.3.1 Selection Criteria 
Intake assessments were gathered over a one and a half year time line with a total of 350 
patients. Of the obtained intake questionnaires, not all surveys were fully completed, thus 
excluding some individuals from further analysis process. The two main sections in the 
baseline intake assessment questionnaire for this analysis that were the focus for were the 
Eating Habits (18 questions) (Table 1) and Eating Habits Frequency (6 questions) (Table 
2) sections of the assessment. The Eating Habits section instructions are for subjects to 
check to indicate a positive response. Similarly, the Eating Habit Frequency section 
instructions were to check to indicate a full positive response, a partial positive response, 
or a lack of positive response. Lack of positive response was treated as a negative 
response. 
 
After excluding individuals who did not have the Eating Habits and the Eating Habits 
Frequency sections filled out the total of cases available for analysis was 222 patients 
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whom we also had extracted clinical database information. After identifying 3 patients 
who did not have complete information regarding visits, a final total of data for 219 
patients was used for the current analysis. Subject data were then split into two groups; 
records from subjects with two visits that could be used to look at baseline predictors and 
weight loss and records from those who did not have two consecutive measurements for 
assessing weight loss. Individuals who had two visits who also had bariatric surgery 
within 4 years of the extraction were excluded from the weight loss analysis. The total 
population that was excluded was 135 patients, with data from 84 patients available to be 
used for the change in weight analysis (figure 3).  
 
 
 
Parent 
Population – 
1,174 patients 
Surveys 
Collected –  
350 patients 
Surveys 
Completed – 
222 patients 
Final Analysis – 
219 patients 
One Time Visits 
and History of 
Bariatric Surgery 
within 4 Years – 
135 patients 
Multiple Visits – 
84 patients 
Completion 
Criteria 
Incomplete Data –
3 patients 
3/1/2010 – 9/10/2012 
 
Figure 3: Analysis eligibility flow chart. 
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2.3.2 Question Grouping 
Questions from both the Eating Habits and Eating Habit Frequency sections were then 
combined (24 total questions) and split into 6 trait categories (Table 3). These categories 
include preventive medical eating, disordered eating patterns, food insecurity, hunger 
disorder, emotional eating, and craving and binging. Later the craving and binging 
category was separated further into binge eating and craving driven eating to address if 
there was a distinct difference between the individuals who identified as bingers and 
those that identified as cravers or if there was significant overlap between those reporting 
binging and craving. Two questions were discarded due to the fact that they did not fit 
appropriately in the specific categories that were established. These included the “I make 
myself vomit food that I have eaten or take laxatives to get rid of food I have eaten” and 
“I try not to let myself ever get hungry” leaving 22 questions for final analysis.  
 
2.3.3 Answer Coding 
Answers to the questions were coded as 0 for no/never, 1 for sometimes, and 2 for 
yes/often. They were then standardized again to achieve a 0 for no/never, 0.5 for 
sometimes, and 1 for yes/often. One question, “I eat at regular times in the day”, was 
negatively coded with 0 for yes, 1 for sometimes, and 2 for no. The answer coding in 
each category was added together to get a total answer out of the number of questions 
that were in each category. The category totals were as follows (Table 3): -­‐ Preventive medical eating: 2 questions -­‐ Disordered eating patterns: 5 questions -­‐ Food insecurity: 3 questions -­‐ Hunger disorder: 3 questions -­‐ Emotional eating: 1 question -­‐ Craving and binge eating: 8 questions total 
o Binge eating was later split into two categories: binge eating (6 
questions) and craving driven eating (2 questions) 
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The answer total of each category was then divided by the number of questions that were 
in the category to have each category’s rating on a scale of one for equal weight between 
categories (e.g. medical reason totals answer total/2) then multiplied by 100. Thus, a 
larger number within each category suggests a greater response within that category.  
 
2.4 Statistical Analysis 
Data were analyzed using SAS (version 9.3, SAS Institute Inc., Cary, NC). Descriptive 
statistics and correlations were run to gain an understanding of the patient population that 
is seen at the MWM clinic and used to assess confounding factors related to weight loss. 
Analysis included calculating the mean, frequency, and the P-value to compare groups 
and find significant difference at the 0.05 significance level (Appendix 1). Regression 
analysis was performed to determine the correlation and odds ratio between category 
intensity and weight loss, percent weight loss, number of follow-up months, and 5% and 
10% weight loss success adjusted for gender. Linear regression was used to assess the 
strength of category responses with the decrease in weight per 30 days, percent decrease 
in weight per 30 days, and follow-up months.  
 
Part 3: Results 
3.1 Demographics 
Baseline demographic information is presented for our subjects in Table 4 (information 
regarding total population and excluded population can be seen in Table 1 and Table 2, 
respectively, in Appendix 2). A total of 84 patients were included in our subject analysis 
with 57 females (68%) and 27 males (32%).  Baseline weight for our subject population 
was 263 ± 74 pounds with females having a mean of 248 ± 67 pounds and males having a 
mean of 296 ± 87 pounds. Baseline BMI averaged 41 ± 9 kg/m2 for females and 42 ± 10 
kg/m2 for males, with a population mean of 41 ± 9 kg/m2. There was no significant 
correlation between baseline age or BMI. Statistical significance was seen between 
gender and baseline weight with a P-value of 0.005 (0.05 significance level). Mean age 
for the group was 47 ± 13 years (mean age for women: 46 ± 14 years; mean age for men: 
49 ±11 years). Additionally, more individuals who were not included in the weight 
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change analysis reported food insecurity (n = 51; 38%) than those who were included in 
the weight change analysis (n = 23; 27%). This suggests that individuals may not have 
returned for additional visits due to low socioeconomic status. 
 
Comorbidities that were seen frequently among females include Cardiovascular Disease 
(n = 26; 42%), chronic pain (n = 24; 42%), and hypertension (n = 22; 38%). Among 
males type 2 diabetes (n = 16; 59%), Cardiovascular Disease (n = 13; 48%), and 
hypertension (n = 13; 48%)were also seen at relatively high rates. There was a significant 
difference between males and females in the occurrence of type 2 diabetes (male: n = 16 
(59%); female: n = 10 (18%); P = <0.001) perhaps related to differences in gender-related 
body fat distribution (Table 5). Comorbidities for the total population and for the 
excluded group can be seen in Appendix 2, Table 3 and Table 4. 
 
3.2 Medication Usage 
Type 2 diabetes was seen in 26 of the 84 individuals (31%). Of these individuals with 
diabetes, 50% (n = 13) were reported to be on GLP-1 agonists, 50% (n = 13) were on 
insulin, and 38% (n = 10) were on both GLP-1 agonists and insulin (Table 6). 
 
Other medications that were of interest to the study included topiramate, naltrexone, and 
phentermine, along with the GLP-1 agonists and insulin that were prescribed at any time 
during the extraction. Topiramate was reported in 40% (n = 34; female: n = 22 (39%); 
male: n = 12 (44%)), naltrexone in 27% (n = 23; female: n = 18 (32%); male: n = 5 
(19%)), and phentermine in 27% (n = 23; female: n = 16 (28%); male: n = 7 (26%)). 
Seventeen individuals reported using GLP-1 agonists (20%; female: n = 9 (16%); male: n 
= 8 (30%)) and insulin was prescribed to 15 (18%; female: n = 6 (11%); male: n = 9 
(33%)) (Table 7). Total population medication usage can be seen in Appendix 2 Table 5. 
 
Of the 75 individuals who identified as having a presence of craving and binge eating, 44 
(59%) were taking naltrexone, topiramate, or both. Naltrexone had been taken to 13 
people (17%), 21 had been on topiramate (48%), and 10 had taken both (13%).  Of the 
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individuals who only identified as cravers (n = 6), 2 were taking naltrexone only (33%), 2 
were on topiramate only (33%), and 2 used both (33%). Individuals who identified as 
only binger eaters (n = 15), 3 were taking naltrexone only (20%), 5 were on topiramate 
only (33%), 2 were using both (13%), and 5 were not taking either (33%). 
 
3.3 Weight Loss Barrier Scores 
Mean strength of baseline trait scores for each weight loss barrier category was obtained 
for the total population (Appendix 2: Table 5; by gender Appendix 2: Table 6), our 
subject population (Table 8; by gender Table 9), and the excluded population (Appendix 
2: Table 7; by gender Appendix 2: Table 8). Though none of the difference in mean 
scores reached significance in our 84 subjects, highest mean scores were seen in the 
emotional eating (65.48 ± 47.20), craving driven eating (46.69 ± 36.95), disordered 
eating (36.90 ± 23.28), and craving combined with binging (34.29 ± 23.28) categories. 
Hunger disorder had a lower mean strength of trait score of 30.92 ± 26.98. Strength of 
trait scores among our subjects was lowest for preventive medical eating (12.80 ± 22.79) 
and food insecurity (10.28 ± 28.30). 
 
Mean scores of each category analyzed by gender showed significant difference in the 
emotional eating weight loss barrier category (72.81 ± 44.38 vs. 50.0 ± 50.0 for women 
vs. men respectively; P = 0.038) (Table 9). Among females the strongest score was 
emotional eating (72.81 ± 44.39), followed by craving driven eating (50.82 ± 36.25), 
disordered eating (39.65 ± 24.05), and craving and binging (37.26 ± 22.27) categories. 
Males presented strongest associations with the emotional eating (50.0 ± 50.0), craving 
driven eating (37.96 ± 37.58), hunger disorder (31.41 ± 22.40), and disordered eating 
(31.11 ± 20.82) categories. Mean score of binge eating only among females was 32.54 ± 
23.11 and males 24.70 ± 22.54 (P = 0.147). Craving driven eating only scores for females 
was 50.82 ± 36.25 and 37.96 ± 37.58 for males (P = 0.137). 
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3.4 Months of Follow-up and Weight Loss 
Mean months of follow-up, change in weight, and percent change in weight are presented 
in Table 10 for our subject population, as well as separated by gender with the P-values 
reported. Mean months of follow-up for our subjects (n = 84) was 4.05 ± 2.93       
(women: 4.239 ± 3.293; men: 3.664 ± 1.948). Significant difference was seen for the 
follow-up months with a P-value of 0.041. Change in weight per 30 day increments had a 
mean decrease of 2.62 ± 4.05 pounds. The mean percent change in weight per 30 days 
showed a decrease of 0.96 ± 1.46 percent for all of our subjects. Females exhibited a 
mean decrease of 2.13 ± 3.47 pounds and a mean percent decrease of 0.82 ± 1.40 per 30 
days. For males a mean decrease in weight over 30 days was 3.65 ± 4.99 pounds and a 
mean percent decrease per 30 days of 1.26 ± 1.56. Neither change in weight per 30 days 
or percent change in weight per 30 days was significantly different between males and 
females.  
 
Weight loss success was measured in two categories: 5% and 10% of baseline weight 
(Table 11). Among the 42 (50%) individuals of our total subject population who reached 
5% success, 29 (49%) were female and 14 (52%) were male (P = 0.815). The highest 
success rate of 10% baseline weight was seen in 23 (27%). Thirteen females (23%) and 
10 males (37%) were able to reach this weight loss benchmark (P = 0.172) in our subject 
population. No significance difference was seen when comparing the percentage of 
females and males who are able to achieve the 5% and 10% weight loss success levels.  
 
3.5 Presence of Categories 
The presence of a category, defined as a subject reporting any level of positive response 
to a given baseline trait question group category, was analyzed by gender and tested for 
significance. A single positive response within each category formed the reference 
population. Significance was seen with the presence of emotional eating (74% vs. 52% 
for females vs. males respectively; P = 0.047) (Table 12). Trend level significance was 
seen with the presence of craving driven eating by gender (77% vs. 59% for females vs. 
males respectively; P = 0.089). The category with the highest presence in females was the 
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craving and binging combined category (n = 52; 91%), followed by disordered eating     
(n = 5; 88%), the binge eating only (n = 48; 84%), and the craving driven eating only     
(n = 44; 77%) categories. Males showed highest presence of disordered eating (n = 23; 
85%), craving and binging combined (n = 23; 85%), hunger disorder (n = 21; 78%), and 
binge eating alone (n = 21; 78%). 
 
Of the 75 patients who were identified as having craving and binging traits there were 52 
females and 23 males. Fifteen of these individuals (20%) answered yes to having a binge 
eating presence without a craving driven eating presence (male: 7; female: 8). Six of the 
75 individuals (8%) answered yes to having craving driven eating without the presence of 
binge eating (male: 2; female: 4). Of the 75 individuals, 54 people (72%) identified as 
having both binge eating and craving driven eating (male: 14; female: 40) (Table 13). No 
significance was seen between males and females who identified as binge eaters, craving 
driven eaters, or both. 
 
3.6 Regression Analysis 
3.6.1 Linear Regression 
Linear regression was performed to determine the relationship between the presence of a 
weight loss barrier category and the change in weight per 30 days, the percent change in 
weight per 30 days, and the follow-up months (Table 14). Significant difference was seen 
between individuals who did not have presence of food insecurity in change in weight per 
30 days and percent change in weight per 30 days (P = 0.017 and 0.008 respectively) 
compared to those who did have the presence of food insecurity. The presence of any 
other weight loss barrier category did not show significance or trend level significance in 
change in weight per 30 days, percent change in weight per 30 days, or follow-up months 
compared to those who did not have presence of the category. 
 
Similarly, linear regression was used to analyze the relationships between the strength of 
weight loss barrier category score and change in weight per 30 days, the percentage 
change in weight per 30 days, and follow-up months (Table 15). Response to the craving 
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and binging category was significant in predicting the increase in weight per 30 days (P = 
0.027; beta coefficient: 4.21 ± 1.9). With an increase in the response to the craving and 
binging category there is less weight loss per 30 days and percent weight loss per 30 days 
than those who do not identify as having presence in this category. No other category had 
significant findings between strength of category response and the decrease in weight, 
percent decrease in weight, or months of follow-up. Trend level significance was seen 
between presence of craving and binging and percent weight change per 30 days (4.21 ± 
1.9; P = 0.058), binge eating presence and the change in weight and percent change in 
weight per 30 days (3.76 ± 1.9 and 1.20 ± 0.68 respectively; P = 0.050 and 0.084 
respectively), and craving driven eating and the change in weight per 30 days (2.18 ± 1.2; 
P = 0.07). 
 
3.6.2 Logistic Regression 
Logistic regression was performed to analyze the odds ratios, after adjusting for gender, 
comparing the odds of each level of weight loss success (5% and 10% of baseline) 
between those that had reported the condition (reference level) and those who did not 
(Table 16). Highest odds were seen in the individuals not reporting food insecurity. The 
odds of 5% success in those who did not report food insecurity were 4.1 times the odds of 
5% success for those who did report food insecurity (P = 0.01). Trend level significance 
showed differences among those that reported craving and binging and binge eating in 
10% success. Individuals who did not have presence of craving and binging were 3.7 
times more likely to achieve 10% weight loss compared to those who did report craving 
and binging. Those who did not report binge eating were 2.8 times more likely to achieve 
10% weight loss compared to those who did report binge eating (P = 0.087). No 
significance was reached for individuals who did not report preventive medical eating, 
disordered eating, hunger disorder, emotional eating, and craving driven eating at both 
the 5% and 10% weight loss success levels. 
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Part 4: Discussion 
The objective of this study was to analyze the baseline traits in individuals at the 
University of Minnesota Adult Medical Weight Management Clinic in relation to weight 
loss outcomes. Mean months of follow-up, weight loss in pounds, percent weight loss, 
and success rates of 5% and 10% of baseline weight were analyzed. Intake assessments 
were utilized to determine which baseline traits were present and the strength and later 
used to determine if these baseline factors could predict how well an individual might do 
with weight loss. We found that individuals who reported food insecurity had 
significantly less weight loss per 30 days and percent weight change per 30 days 
compared to those who did not report food insecurity. Individuals who reported food 
insecurity were more likely to not return to the Medical Weight Management clinic, 
potentially contributing as a major barrier to successful weight loss. Overall, non-hunger 
related baseline traits were more common among our subjects with few baseline traits 
predicting how well an individual will achieve weight loss success. 
 
There have been studies looking at baseline traits and weight loss outcomes.216 - 222 In 
these other reports the relationships between baseline traits in relation to weight change 
varied significantly. In some cases there were interactions between predictors, behaviors, 
treatment types, and the overall difference between the patient populations, which likely 
contributed to variability in the relationships between baseline traits and subsequent 
weight loss.218, 219, 221 There have been patient-matching treatment algorithms created 
based on degree of overweight, waist circumference, cardiovascular disease risk factors, 
however, future interactions should include psychological factors such as attitude, 
emotional distress, depression, and body image.219, 223, 224 
 
Several retrospective studies have identified behavior and psychological factors that are 
correlated to unsuccessful long-term weight loss.225, 226, 227 There is still however quite a 
bit of variability with these predicting factors with only 20-25% of weight loss predicted 
by baseline variables.219, 222, 228 Some investigators have reported little or no association 
between weight changes during treatment and baseline presence of binge eating while 
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others have found binge eating to be an important predictor in lack of weight loss 
success.219, 229, 230 In our own study, change in weight per 30 days was related to strength 
of baseline self-reported craving and binging behavior (P = 0.027).  
 
The difference between men and women has been studied for many different factors 
including weight change, success in maintaining weight loss, and presence of baseline 
traits. In females the overall decrease in weight and likelihood of maintaining the weight 
loss is lower than with males.231 These results are consistent with findings that women 
are more likely to diet than men are, suggesting that women have more occurrence of 
weight cycling.231 Although not statistically significant, our study showed that women 
had less weight loss than men in both pounds lost per 30 days and percent body weight 
loss per 30 days. We did find a self-reported difference in the presence of baseline traits, 
which could have contributed to the overall decreased success of weight loss of women. 
Other studies have found the occurrence of binge eating disorder to be higher among 
females compared to males 3.5% vs. 2% respectively in one study.199 In our study 
relatively high amounts of binge eating were reported in both males (85%) and females 
(97%), following the trend of an increasing number of obese individuals around the 
United States exhibiting symptoms of binge eating disorder.199  
 
Low socioeconomic status has been linked to obesity, with current obesity rates rising 
among individuals of low socioeconomic status.19 Current evidence suggests that 
individuals, both men and women, who are mildly food-insecure are more likely to be 
overweight and obese. However, women have been shown to have a higher association 
between low socioeconomic status with overweight and obesity compared to men.180, 181, 
182 Our findings showed that those who reported food insecurity lost less weight than 
those who did not (1.2 ± 0.8 pounds vs. 3.5 ± 0.5 pounds respectively, expressed as 
weight change per 30 days; P = 0.017; and 0.36 ± 0.3 percent vs. 1.3 ± 0.2 percent 
respectively, expressed as percent weight change per 30 days; P = 0.008). The odds of 
5% and 10% weight loss success in individuals who presented food insecurity were 
significantly lower, P = 0.010 and P = 0.030 respectively. 
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Our study was limited by having completed questionnaires in only a small percentage of 
the overall database population and limited time frame in which data was collected. Our 
final sample size was relatively small compared to the overall population. With self-
reported responses there is the possibility that an individual may respond inaccurately 
based on providing what the provider may want to hear. There may be issues with recall 
and thus the accuracy of answers and misunderstanding of the questions being asked. 
Another limitation to the study was the questionnaire itself. Although it was adapted from 
and utilized similar wording as validated questionnaires, this specific questionnaire has 
not been validated. Issues with patient retention can be seen by the number of patients 
with at least two visits available for weight change analysis (n = 84) after starting with 
219 in the total population. This lack of retention and resulting small sample size may 
limit the generalizability of our results. However, we found no difference in demographic 
and presence of baseline traits among the individuals. Adjustments for medication usage 
were not carried out in this analysis, which could have affected the ability to see the 
relationship between reported traits at baseline and subsequent weight loss success. 
 
In conclusion, we examined a number of self-reported baseline traits within our clinic 
population and found that there was a significant difference in weight loss comparing 
those who identified as being food insecure and those who did not. Regarding strength of 
baseline trait for the other examined categories, including preventive medical eating, 
disordered eating, hunger disorder, emotional eating, craving and binging, we did not find 
significant differences in weight loss. In regards to presence of the baseline trait 
categories and subsequent weight loss success, we found individuals who reported food 
insecurity were less likely to achieve 5% success. Regarding any level of presence of the 
baseline trait categories and subsequent weight loss success, we found that presence of 
baseline traits did not predict weight loss success for the preventive medical eating, 
disordered eating, hunger disorder, emotional eating, and craving and/or binging 
categories. Presence of low socioeconomic status within our population exhibited less 
weight loss per 30 days, percent weight loss per 30 days, and reaching the 5% and 10% 
success level. 
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Table 1: Eating Habit Section 
 
Eating Habit Questions 
1. I eat at regular times in the day, that is breakfast, lunch, dinner 
2. I eat most of my food at the end of the day 
3. Most of the food I eat requires very little cooking or preparation 
4. I find myself hiding food or food wrappers 
5. I eat most of my meals in front of the TV or computer 
6. I eat when I’m depressed, stressed, bored, or to reward myself 
7. I feel hungry all the time, even if I have just eaten 
8. I feel like I am always thinking about eating 
9. When I have a craving I try not to give in but usually end up giving in 
10. Once I start eating I have a hard time stopping 
11. I try not to let myself ever get hungry 
12. Feeling full after a meal is important to me 
13. I have stomach acid or pain and eating makes it feel better 
14. I eat extra snacks to prevent or correct low blood sugars 
15. I wake up at night to eat 
16. I worry about not having enough food to eat 
17. I have been to the food shelf at least a few times this year 
18. A lack of money keeps me from eating a healthy diet 
 
 
Table 2: Eating Habit Frequency Section 
 
Eating Habit Frequency Questions 
1. I tend to over eat. For example I can eat almost a whole box of cereal, a large bag of chips, or a 
loaf of bread in one sitting 
2. I feel out of control when I eat 
3. I make myself vomit foods that I have eaten or take laxatives to get rid of food I’ve eaten 
4. I eat large amounts when I am not hungry 
5. I eat until I am uncomfortably full 
6. I feel bad about myself or guilty after I over eat 
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Table 3: Category and Questions 
 
Category Number of Questions Questions 
Preventive Medical Eating 2 -­‐ I have stomach acid or pain and 
eating makes it feel better -­‐ I eat extra snacks to prevent or 
correct low blood sugars 
Disordered Eating Patterns 5 -­‐ I wake up at night to eat -­‐ I eat at regular times in the day, 
that is breakfast, lunch, dinner -­‐ I eat most of my food at the end of 
the day -­‐ Most of the food I eat requires very 
little cooking or preparation -­‐ I eat most of my meals in front of 
the TV or computer 
Food Insecurity 3 -­‐ I worry about not having enough 
food to eat -­‐ I have been to the food shelf at 
least a few times this year -­‐ A lack of money keeps me from 
eating a healthy diet 
Hunger Disorder 3 -­‐ I feel hungry all the time, even if I 
have just eaten -­‐ Feeling full after a meal is 
important to me -­‐ I try not to let myself ever get 
hungry 
Emotional Eating 1 -­‐ I eat when I’m depressed, stressed, 
bored, or to reward myself 
*Binge Eating 6 
 
-­‐ I find myself hiding food or food 
wrappers -­‐ Once I start eating I have a hard 
time stopping -­‐ I tend to over eat. For example I 
can eat almost a whole box of 
cereal, a large bag of chips, or a 
loaf of bread in one sitting -­‐ I feel out of control when I eat -­‐ I eat until I am uncomfortably full -­‐ I feel bad about myself or guilty 
after I over eat 
*Craving Driven Eating 2 
 
-­‐ I feel like I am always thinking 
about food -­‐ When I have a craving I try not to 
give in but usually end up giving in 
* Binge eating and craving driven eating is a subset of craving and binging 
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Table 4: Baseline Data for Our Patients: Male vs. Female: Values are mean ± SD 
 
 Female Male P Value 
N 57 27  
Age (years) 46 ± 14 49 ±11 0.244 
Baseline Weight 
(lbs) 
248 ± 67 296 ± 87 0.005 
Height (in) 65 ± 3 70 ± 3 <0.001 
BMI 41 ± 9 42 ± 10 0.904 
Race  
    Caucasian  
    African 
    African-American 
    Other 
    Unknown 
 
43 (75%) 
0 (0%) 
0 (0%) 
7 (12%) 
7 (12%) 
 
19 (70%) 
1 (4%) 
1 (4%) 
1 (4%) 
5 (19%) 
 
0.185 
Bariatric Surgery 
History 
     Yes 
 
 
4 (7%) 
 
 
1 (4%) 
 
 
0.549 
BP 
    Diastolic 
    Systolic 
 
74 ± 11 
128 ± 15 
 
76 ± 10 
131 ± 15 
 
0.475 
0.482 
Relationship Status 
    Single 
    Partnered 
    Unknown 
 
32 (56%) 
24 (42%) 
1 (2%) 
 
11 (41%) 
15 (56%) 
1 (4%) 
 
0.396 
Socioeconomic 
Status 
Disabled 
      No 
     Disabled 
     Unknown 
Employed 
     Employed 
     On Disability 
     Unemployed 
     Unknown 
 
 
15 (26%) 
3 (5%) 
39 (64%) 
 
8 (14%) 
3 (5%) 
8 (14%) 
38 (67%) 
 
 
7 (26%) 
2 (7%) 
18 (67%) 
 
6 (22%) 
2 (7%) 
0 (0%) 
19 (70%) 
 
 
0.927 
 
 
 
0.195 
Smoking 
     Former 
     Current 
 
5 (9%) 
4 (7%) 
 
4 (15%) 
1 (4%) 
 
0.448 
Alcohol 
    Current Drinker 
 
4 (7%) 
 
2 (7%) 
 
0.297 
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Table 5: Comorbidities for Our Subjects by Gender: Male (n = 27) Female (n = 57) 
 
 Female Male P-value 
SA 
    Yes 
 
10 (18%) 
 
8 (30%) 
 
0.207 
GERD 
    Yes 
 
7 (12%) 
 
2 (7%) 
 
0.500 
OA 
    Yes 
 
8 (14%) 
 
2 (7%) 
 
0.381 
CP 
    Yes 
 
24 (42%) 
 
9 (33%) 
 
0.442 
CVHD 
    Yes 
 
26 (46%) 
 
13 (48%) 
 
0.828 
HTN 
    Yes 
 
22 (38%) 
 
13 (48%) 
 
0.407 
HLIP 
    Yes 
 
15 (26%) 
 
11 (41%) 
 
0.182 
BP 
    Yes 
 
4 (7%) 
 
1 (4%) 
 
0.549 
DEP 
    Yes 
 
19 (33%) 
 
6 (22%) 
 
0.298 
DM2 
    Yes 
 
10 (18%) 
 
16 (59%) 
 
<0.001 
DM1 
    Yes 
 
0 (0%) 
 
1 (4%) 
 
0.144 
HYPOT4 
    Yes 
 
8 (14%) 
 
1 (4%) 
 
0.153 
HPTH 
    Yes 
 
2 (4%) 
 
0 (0%) 
 
0.325 
PCOS 
    Yes 
 
3 (5%) 
 
0 (0%) 
 
0.225 
SD 
    Yes 
 
14 (25%) 
 
11 (41%) 
 
0.130 
SA: Sleep Apnea: GERD: Gastrointestinal Reflux Disease; OA: Osteoarthritis; CP: Chronic 
Pain; CVHD: Cardiovascular Heart Disease; HTN: Hypertension; HLIP: Hyperlipidemia; BP: 
Bipolar Disorder; DEP: Depression; DM2: Type 2 Diabetes; DM1: Type 1 Diabetes;  
HYPOT4: Hyperperothyroidism; HPTH: Hypothyroidism; PCOS: Polycystic Ovarian Syndrome; 
SD: Sleeping Disorders 
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Table 6: Medications of Diabetics:  
 
 Total Population (n = 219) Our Subjects (n = 84) 
Reported Diabetes 53 26 
GLP-1 Agonists 25 (47%) 13 (50%) 
Insulin 21 (40%) 13 (50%) 
Both 15 (28%) 10 (38%) 
 
 
Table 7: Medication Usage for Our Subjects: 
 
 Our Subjects      
(n = 84) 
Female (n = 57) Male (n = 27) P-value 
GLP-1 Agonists 17 (20%) 9 (16%) 8 (30%) 0.140 
Insulin 15 (18%) 6 (11%) 9 (33%) 0.011 
Topiramate 34 (40%) 22 (39%) 12 (44%) 0.610 
Naltrexone 23 (27%) 18 (32%) 5 (19%) 0.210 
Phentermine 23 (27%) 16 (28%) 7 (26%) 0.837 
 
 
Table 8: Mean Weight Loss Barrier Scores: n = 84 
 
Category Mean SD 
Preventive Medical Eating 12.80 22.79 
Disordered Eating 36.90 23.28 
Food Insecurity 10.28 20.30 
Hunger Disorder 30.92 26.98 
Emotional Eating 65.48 47.20 
Craving and Binging 
    Binge Eating* 
    Craving Driven Eating*  
34.29 
30.02 
46.69 
23.28 
23.08 
36.95 
* Included in Craving and Binging score 
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Table 9: Mean Weight Loss Barrier Scores Compared Between Males (n = 27) and 
Females (n = 57) for Our Subjects. 
 
Category Females 
Mean ± SD 
Males 
Mean ± SD 
P Value  
Preventive Medical Eating 14.04 ± 22.17 10.19 ± 24.28 0.473 
Disordered Eating 39.65 ± 24.05 31.11 ± 20.82 0.117 
Food Insecurity 9.92 ± 19.34 11.04 ± 22.57 0.816 
Hunger Disorder 30.68 ± 29.08 31.41 ± 22.40 0.910 
Emotional Eating 72.81 ± 44.39 50.00 ± 50.00 0.038 
Craving and Binging 
    Binge Eating* 
    Craving Driven Eating* 
37.26 ± 22.27 
32.54 ± 23.11 
50.82 ± 36.25 
28.00 ± 24.53 
24.70 ± 22.54 
37.96 ± 37.58 
0.089 
0.147 
0.137 
* Included in Craving and Binging score 
 
 
Table 10: Mean Months of Follow-up, Change in Weight (Pounds) and Percent 
Change in Weight per 30 Days 
 
 Our Population Female Male P-value 
N 84 57  27  
Months of follow 
up 
 
4.05 ± 2.93 
 
4.24 ± 3.29 
 
3.66 ± 1.95 
 
0.405 
Change in weight 
per 30 days 
(Pounds) 
 
 
-2.62 ± 4.05 
 
 
-2.13 ± 3.47 
 
 
-3.65 ± 4.99 
 
 
0.109 
Percent change in 
weight per 30 
days 
 
 
-0.96 ± 1.46 
 
 
-0.82 ± 1.40 
 
 
-1.26 ± 1.56 
 
 
0.204 
*Negative value is equal to weight loss (pounds) and percent weight loss 
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Table 11: Weight Loss Success Levels 
 
 Total Population 
(n = 84) 
Female 
(n = 57) 
Male 
(n = 27) 
P-value 
5% Success 
    Yes 
 
42 (50%) 
 
28 (49%) 
 
14 (52%) 
 
0.815 
10% Success 
    Yes 
 
23 (27%) 
 
13 (23%) 
 
10 (37%) 
 
0.172 
*Percent of individuals achieving weight loss success levels 
 
Table 12: Presence of Weight Loss Barriers: values reported are percent reporting the 
condition  
 
 Female (n = 57) Male (n = 27) P-value 
Preventive Medical Eating 17 (30%) 5 (19%)  0.271 
Disordered Eating 50 (88%) 23 (85%)  0.748 
Food Insecurity 16 (28%) 7 (26%) 0.837 
Hunger Disorder 36 (63%) 14 (52%) 0.180 
Emotional Eating 42 (74%) 14 (52%) 0.047 
Craving and Binging 
    Binge Eating* 
    Craving Driven Eating* 
55 (97%) 
48 (84%) 
44 (77%) 
23 (85%) 
21 (78%) 
16 (59%) 
0.403 
0.472 
0.089 
*Presence was defined as having at least 1 positive response to the weight loss barrier 
category 
 
Table 13: Binge Eaters and Craving Driven Eaters 
 
 Total Identifiers    
(n = 75) 
Female (n = 52) Male (n = 23) P-value 
Binge Presence 
Only 
15 (20%) 8 (15%) 7 (30%) 0.133 
Craving Presence 
Only 
6 (8%) 4 (8%) 2 (9%) 0.883 
Presence of Both 54 (72%) 40 (77%) 14 (61%) 0.153 
*Identifiers are individuals with at least 1 positive response in the weight loss barrier 
category 
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Table 14: Linear Regression Analysis: mean weight changes ± SE, adjusted for gender, 
negative values represent weight loss 
 
 Change in Weight per 
30 days (Pounds) 
% Change in Weight 
per 30 days 
Follow Up Time 
(Months) 
Preventive Medical 
Eating 
    Yes 
    No 
    P-value 
 
 
-1.7 ± 0.9 
-3.3 ± 0.5 
0.120 
 
 
-0.73 ± 0.3 
-1.1 ± 0.2 
0.268 
 
 
4.2 ± 0.7 
3.9 ± 0.4 
0.709 
Disordered Eating 
    Yes 
    No 
    P-value 
 
-2.8 ± 0.5 
-3.7 ± 1 
0.474 
 
-1.0 ± 0.2 
-1.3 ± 0.4 
0.474 
 
3.8 ± 0.4 
4.7 ± 0.9 
0.359 
Food Insecurity 
    Yes 
    No 
    P-value 
 
-1.2 ± 0.8 
-3.5 ± 0.5 
0.017 
 
-0.36 ± 0.3 
-1.3 ± 0.2 
0.008 
 
4.7 ± 0.6 
3.7 ± 0.4 
0.146 
Hunger Disorder 
    Yes 
    No 
   P-value 
 
-2.9 ± 0.5 
-2.8 ± 0.8 
0.946 
 
-1.1 ± 0.2 
-0.97 ± 0.3 
0.787 
 
4.2 ± 0.4 
3.4 ± 0.6 
0.233 
Emotional Eating 
    Yes 
    No 
    P-value 
 
-2.6 ± 0.6 
-3.4 ± 0.8 
0.413 
 
-0.95 ± 0.2 
-1.2 ± 0.3 
0.500 
 
4.3 ± 0.4 
3.4 ± 0.6 
0.201 
Craving and Binging 
    Yes 
    No 
    P-value 
 
-2.7 ± 0.5 
-3.9 ± 1 
0.412 
 
-0.98 ± 0.2 
-1.4 ± 0.5 
0.374 
 
4.1 ± 0.4 
3.1 ± 1 
0.340 
Binge Eating* 
    Yes 
    No 
    P-value 
 
-2.8 ± 0.5 
-3.4 ± 1 
0.569 
 
-0.99 ± 0.2 
-1.3 ± 0.4 
0.502 
 
4.11 ± 0.4 
3.3 ± 0.8 
0.311 
Craving Driven Eating* 
    Yes 
    No 
    P-value 
 
-2.4 ± 0.6 
-3.8 ± 0.8 
0.155 
 
-0.9 ± 0.2 
-1.3 ± 0.3 
0.349 
 
3.6 ± 0.4 
4.7 ± 0.6 
0.127 
* Included in Craving and Binging score 
** Negative values are weight loss (pounds) and percent weight loss 
*** Presence was defined as having at least 1 positive response in the weight loss barrier 
category 
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Table 15: Simple Linear Regression: values are ± SD 
 
 Change in Weight per 
30 Days 
% Change in Weight 
per 30 Days 
Follow-up Time 
(Months) 
Preventive Medical 
Eating 
    Parameter Estimate 
    P-value 
 
 
1.73 ± 2.0 
0.379 
 
 
0.24 ± 0.71 
0.736 
 
 
1.08 ± 1.4 
0.44 
Disordered Eating 
    Parameter Estimate 
    P-value 
 
0.47 ± 1.9 
0.807 
 
0.42 ± 0.69 
0.543 
 
-2.54 ± 1.4 
0.065 
Food Insecurity 
    Parameter Estimate 
    P-value 
 
2.69 ± 2.2 
0.221 
 
1.15 ± 0.78 
0.146 
 
1.64 ± 1.6 
0.302 
Hunger Disorder 
    Parameter Estimate 
   P-value 
 
-0.64 ± 1.7 
0.699 
 
-0.36 ± 0.60 
0.547 
 
-0.12 ± 1.2 
0.918 
Emotional Eating 
    Parameter Estimate 
    P-value 
 
0.86 ± 0.94 
0.365 
 
0.20 ± 0.34 
0.551 
 
0.98 ± 0.68 
0.151 
Craving and Binging 
    Parameter Estimate 
    P-value 
 
4.21 ± 1.9 
0.027 
 
1.30 ± 0.68 
0.058 
 
-0.81 ± 1.4 
0.559 
Binge Eating* 
    Parameter Estimate 
    P-value 
 
3.76 ± 1.9 
0.050 
 
1.20 ± 0.68 
0.084 
 
-0.18 ± 1.4 
0.898 
Craving Driven 
Eating* 
    Parameter Estimate 
    P-value 
 
 
2.18 ± 1.2 
0.070 
 
 
0.64 ± 0.43 
0.142 
 
 
-0.99 ± 0.87 
0.260 
*Presence was defined as having at least 1 positive response 
**A positive value represents weight gain and increase in months of follow-up 
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Table 16: Logistic Regression Analysis: Odds ratio (95% CI), adjusted for gender, 
comparing odds of each level of weight-loss success between those not reporting the 
condition and those who did report the condition (reference level). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Included in Craving and Binging score 
 
 
 
 
 
 
 
 
 5% Success 10% Success 
No Preventive Medical 
Eating vs Preventive 
Medical Eating 
    P-value 
1.63 (0.61, 4.4) 
 
 
0.333 
1.85 (0.54, 6.3) 
 
 
0.327 
No Disordered Eating vs. 
Disordered Eating 
    P-value 
0.81 (0.23, 2.9) 
 
0.740 
1.59 (0.41, 6.1) 
 
0.503 
No Food Insecurity vs. Food 
Insecurity 
    P-value 
4.07 (1.4, 11.8) 
 
0.010 
5.59 (1.2, 26.5) 
 
0.030 
No Hunger Disorder vs. 
Hunger Disorder 
    P-value 
0.91 (0.36, 2.3) 
 
0.840 
0.997 (0.35, 2.9) 
 
0.955 
No Emotional Eating vs. 
Emotional Eating 
    P-value 
0.98 (0.39, 2.5) 
 
0.959 
0.94 (0.33, 2.7) 
 
0.900 
No Craving and Binging vs. 
Craving and Binging 
    P-value 
2.15 (0.50, 9.3) 
 
0.306 
3.73 (0.89, 15.7) 
 
0.072 
No Binge Eating* vs. Binge 
Eating*  
    P-value 
1.62 (0.52, 5.1) 
 
0.404 
2.78 (0.86, 9.0) 
 
0.087 
No Craving Driven Eating* 
vs. Craving Driven Eating 
    P-value 
1.25 (0.48, 3.3) 
 
0.655 
1.77 (0.62, 5.0) 
 
0.282 
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Summary and Conclusions 
An increasing amount of individuals being classified as obese and an increased need for 
treatment of obesity and its comorbidities are important public health issues around the 
world. By assessing a patient carefully prior to or during the initial visit, there is the 
possibility of designing more individualized weight loss plans. This can lead to better 
treatment options and overall greater weight loss success within the clinic.  
 
With the increasing number of treatment approaches that are available to individuals, it 
seems that individuals should be exhibiting high levels of success. However, this is not 
the case. There are highly variable amounts of weight loss success among individuals 
who are able to lose weight. Many factors contribute to the overall success, or lack there 
of, including age, physical ability, genetics, and environment. It is difficult to fully 
explain the reasons for the high amount of variability in weight loss results and why some 
individuals are better able to adopt attitude and behavior change and others are not.155 
However, baseline predictor trait assessment followed by better designed targeted 
treatment approach has the potential to provide patients with the most viable options for 
successful weight loss and long term weight maintenance. 
 
The focus of our study was to take a clinical intake assessment and use the answers to 
find a relationship between presence of weight loss barrier traits and subsequent weight 
loss outcomes. In our study the presence of the different categories including: preventive 
medical eating, disordered eating, food insecurity, decreased hunger perception, 
emotional eating, binge eating, and craving driven eating were analyzed for frequency 
between men and women. There were some difference in presence of disordered eating, 
binge eating, and craving driven eating frequency with women tending to have a higher 
prevalence of these issues compared to men. 
 
Additionally, in our study various measures of weight loss and success were utilized 
including the change in weight per 30 days, the percent change in weight per 30 days, and 
success of 5% and 10% loss of baseline weight. There were significant difference in 
  60 
weight loss per 30 days and percent weight loss per 30 days for individuals who had 
presence of food insecurity, those who exhibited binge eating, and those who exhibited 
craving driven eating compared to those that did not. Significance was also seen for 
decreased weight per 30 days (less weight loss) for those who had identified emotional 
eating compared to those who did not (all factors were adjusted for gender). Simple linear 
regression showed significant difference (P = 0.027) between higher scores in the craving 
and binging category and the low amount of weight less per 30 days. 
 
These results provide insight into using baseline clinical intake assessments help target 
weight loss barriers and guide successful treatment. By addressing the key characteristics 
with which an identifies there can be a better understanding of what the issues are, what 
how well that individual will do, and the prospect of assessing better therapeutic plans. 
Only one baseline trait, food insecurity, had significant difference in change in weight per 
30 days and percent change in weight per 30 days. Logistic regression showed that the 
odds ratio for 5% success was higher in individuals who did not have food insecurity 
compared to those who did.  
 
Although limitations were present in this study, the information that was gained can 
improve our understanding of the obese patient population. Predicting baseline traits can 
help identify areas in which an individual will have the greatest issues with weight loss 
and maintenance.  
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Appendix 1: SAS (9.3) Coding 
 
Demo input 
 
data demo; 
infile 'C:\Users\bayer051\Desktop\patientvisitsbaseline-2(5-29-14)-1.csv' dlm = "," 
firstobs = 2; 
input pid include $ age sex $ sbp dbp ht avg_ht wt bmi std_bmi relationship $ race $ 
employed $ 
disabled $ smoking $ alcohol $ history_bs $ med disord socio hungdis emotional binge 
craving; 
run; 
proc print data = demo; 
run; 
proc means data = demo; 
class include; 
var age avg_ht wt std_bmi dbp sbp; 
run; 
proc ttest data = demo; 
class include; 
var age avg_ht wt std_bmi dbp sbp; 
run; 
proc freq data = demo; 
tables include* (sex relationship race employed disabled smoking alcohol 
history_bs)/chisq; 
run; 
data include; 
set demo; 
if include = "no" then delete; 
run; 
proc print data = include; 
run; 
proc means data = include; 
class sex; 
var age avg_ht wt std_bmi dbp sbp; 
run; 
proc ttest data = include; 
class sex; 
var age avg_ht wt std_bmi dbp sbp; 
run; 
proc freq data = include; 
tables sex* (relationship race employed disabled smoking alcohol history_bs)/chisq; 
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run; 
proc means data = demo; 
class sex; 
var med disord socio hungdis emotional binge craving; 
run; 
proc ttest data = demo; 
class sex; 
var med disord socio hungdis emotional binge craving; 
run; 
proc means data = include; 
class sex; 
var med disord socio hungdis emotional binge craving; 
run; 
proc ttest data = include; 
class sex; 
var med disord socio hungdis emotional binge craving; 
run; 
data exclude; 
set demo; 
if include = "yes" then delete; 
run; 
proc print data = exclude; 
run; 
proc means data = exclude; 
var med disord socio hungdis emotional binge craving; 
run; 
proc means data = exclude; 
class sex; 
var med disord socio hungdis emotional binge craving; 
run; 
proc ttest data = exclude; 
class sex; 
var med disord socio hungdis emotional binge craving; 
run; 
 
Comorbidities input 
 
data comorbids; 
infile 'C:\Users\bayer051\Desktop\ICD9-2-5-29-14.csv' dlm = "," firstobs = 2; 
input pid include $ sex $ sa $ gerd $ oa $ cp $ cvhd $ htn $ hlip $ 
bp $ dep $ dm2 $ dm1 $ hypot4 $ hpth $ pcos $ sd $ int $ md $; 
run; 
proc print data = comorbids; 
run; 
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proc freq data = comorbids; 
tables sa gerd oa cp cvhd htn hlip bp dep dm2 dm1 hypot4 hpth pcos sd int md; 
run; 
proc freq data = comorbids; 
tables include*(sa gerd oa cp cvhd htn hlip bp dep dm2 dm1 hypot4 hpth pcos sd int 
md)/chisq; 
run; 
data include; 
set comorbids; 
if include = "no" then delete; 
run; 
proc print data = include; 
run; 
proc freq data = include; 
tables sex * (sa gerd oa cp cvhd htn hlip bp dep dm2 dm1 hypot4 hpth pcos sd int 
md)/CHISQ; 
run; 
 
Medication Input 
 
data medications; 
infile ‘C:\User\bayer051\Desktop\meds.csv’ dlm=’,’ firstobs=2; 
input pid include $ sex $ glp1 insulin top naltrex phen; 
run; 
proc print data = medications; 
run; 
proc freq data = meds; 
tables glp1 insulin top naltrex phen; 
run; 
proc freq data = meds; 
tables sex*(glp1 insulin top naltrex phen)/chisq; 
run; 
 
Binge Crave Frequency Input 
 
data bingecrave; 
infile 'C:\Users\bayer051\Desktop\bingerscravers.csv' dlm = ',' firstobs=2; 
input pid include $ sex $ crav_bing binge crave GLP1 insulin top naltrex phen both 
bineonly craveonly; 
run; 
proc print data = bingecrave; 
run; 
proc freq data = bingecrave; 
table sex*bineonly/chisq; 
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run; 
proc freq data = bingecrave; 
table sex*craveonly/chisq; 
run; 
proc freq data = bingecrave; 
table sex*both/chisq; 
run; 
 
Mean Answers Input 
 
data answers; 
infile 'C:\Users\bayer051\Desktop\patientvisitsbaseline-2(5-29-14)-1.csv' dlm = "," 
firstobs=2; 
input pid include $ age sex $ sbp dbp ht avg_ht wt bmi std_bmi relationship $ race $ 
employment $ disabled $ 
smoking $ alcohol $ history_bs $ med disord socio hungdis emotional crav_bing binge 
crave; 
run; 
proc print data = answers; 
run; 
proc means data = answers; 
var med disord socio hungdis emotional crav_bing binge crave; 
run; 
proc means data = answers; 
class sex; 
var med disord socio hungdis emotional crav_bing binge crave; 
run; 
proc ttest data = answers; 
class sex; 
var med disord socio hungdis emotional crav_bing binge crave; 
run; 
data include; 
set answers; 
if include = 'no' then delete; 
run; 
proc print data = include; 
run; 
proc means data = include; 
var med disord socio hungdis emotional crav_bing binge crave; 
run; 
proc means data = include; 
class sex; 
var med disord socio hungdis emotional crav_bing binge crave; 
run; 
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proc ttest data = include; 
class sex; 
var med disord socio hungdis emotional crav_bing binge crave; 
run; 
data exclude; 
set answers; 
if include = 'yes' then delete; 
run; 
proc print data = exclude; 
run; 
proc means data = exclude; 
var med disord socio hungdis emotional crav_bing binge crave; 
run; 
proc means data = exclude; 
class sex; 
var med disord socio hungdis emotional crav_bing binge crave; 
run; 
proc ttest data = exclude; 
class sex; 
var med disord socio hungdis emotional crav_bing binge crave; 
run; 
 
Regression input 
 
data regression; 
infile 'C:\Users\bayer051\Desktop\changewtanswers5-28-14.csv' missover dlm="," 
firstobs=2; 
input pid include $ sex $ wt bmi std_bmi med disord socio hungdis emotional crav_bing 
binge crave 
d_wt_per30d pcd_wt_per30d success3 success5 success10 follow_up_months; 
med = (med > 0.00); 
disord = (disord >0.00); 
socio = (socio >0.00); 
hungdis = (hungdis >0.00); 
emotional = (emotional >0.00); 
crav_bing = (crav_bing > 0.00); 
binge = (binge >0.00); 
crave = (crave >0.00); 
run; 
proc print data = regression; 
run; 
proc means data = regression; 
class sex; 
var d_wt_per_pcd_wt_per30d follow_up_months; 
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run; 
proc ttest data = regression; 
class sex; 
var d_wt_per30d pcd_wt_per30d follow_up_months; 
run; 
proc freq data = regression; 
tables sex * (success3 success5 success10)/chisq; 
run; 
%macro reg_sex_adjusted (pred= ); 
   proc glm data = regression; 
   class sex &pred; 
   model d_wt_per30d pcd_wt_per30d follow_up_months = sex &pred; 
   lsmeans &pred / stderr pdiff; 
%mend ; 
 
%reg_sex_adjusted (pred= med); 
%reg_sex_adjusted (pred= disord); 
%reg_sex_adjusted (pred= socio); 
%reg_sex_adjusted (pred= hungdis); 
%reg_sex_adjusted (pred= emotional); 
%reg_sex_adjusted (pred= crav_bing); 
%reg_sex_adjusted (pred= binge); 
%reg_sex_adjusted (pred= crave); 
 
%macro log_reg_sex_adjusted (pred= ); 
   proc logistic descending data = regression; 
   class sex &pred; 
   model success3 = sex &pred; 
   run; 
   proc logistic descending data = regression; 
   class sex &pred; 
   model success5 = sex &pred; 
   run; 
   proc logistic descending data = regression; 
   class sex &pred; 
   model success10 = sex &pred; 
%mend; 
 
%log_reg_sex_adjusted (pred= med); 
%log_reg_sex_adjusted (pred= disord); 
%log_reg_sex_adjusted (pred= socio); 
%log_reg_sex_adjusted (pred= hungdis); 
%log_reg_sex_adjusted (pred= emotional); 
%log_reg_sex_adjusted (pred= crav_bing); 
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%log_reg_sex_adjusted (pred= binge); 
%log_reg_sex_adjusted (pred= crave); 
 
 
proc freq data = regression; 
tables sex * (med disord socio hungdis emotional crav_bing binge crave) / chisq; 
run; quit; 
 
SLR Input 
 
data linear; 
infile 'C:\Users\bayer051\Desktop\changewtanswers5-28-14(1).csv' dlm = ',' firstobs=2; 
input PID include $ sex $ wt bmi std_bmi med disord socio hungdis emotional crav_bing 
binge crave 
d_wt_per30d pcd_wt_per30d success3 success5 success10 follow_up_months; 
run; 
 
proc reg data = linear; 
model d_wt_per30d = {med disord socio hungdis emotional crav_bing binge crave}; 
plot d_wt_per30d*{med disord socio hungdis emotional crav_bing binge crave}; 
run; 
quit; 
proc reg data = linear; 
model d_wt_per30d = med; 
plot d_wt_per30d * med; 
run; 
quit; 
proc reg data = linear; 
model pcd_wt_per30d = med; 
plot pcd_wt_per30d*med; 
run; 
quit: 
proc reg data = linear; 
model follow_up_months = med; 
plot follow_up_months*med; 
run; 
quit; 
proc reg data = linear; 
model d_wt_per30d = disord; 
plot d_wt_per30d * disord; 
run; 
quit; 
proc reg data = linear; 
model pcd_wt_per30d = disord; 
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plot pcd_wt_per30d*disord; 
run; 
quit; 
proc reg data = linear; 
model follow_up_months = disord; 
plot follow_up_months*disord; 
run; 
quit; 
proc reg data = linear; 
model d_wt_per30d = socio; 
plot d_wt_per30d * socio; 
run; 
quit; 
proc reg data = linear; 
model pcd_wt_per30d = socio; 
plot pcd_wt_per30d*socio; 
run; 
quit: 
proc reg data = linear; 
model follow_up_months = socio; 
plot follow_up_months*socio; 
run; 
quit; 
proc reg data = linear; 
model d_wt_per30d = hungdis; 
plot d_wt_per30d * hungdis; 
run; 
quit; 
proc reg data = linear; 
model pcd_wt_per30d = hungdis; 
plot pcd_wt_per30d*hungdis; 
run; 
quit: 
proc reg data = linear; 
model follow_up_months = hungdis; 
plot follow_up_months*hungdis; 
run; 
quit; 
proc reg data = linear; 
model d_wt_per30d = emotional; 
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Appendix 2: Supplementary Tables 
 
Table 1: Baseline Data:  Values are mean ± SD  
 
 Total Population Female Male P values 
N 219 156 63  
Age 46 ± 13 45 ± 13 48 ± 13 0.106 
Baseline Weight (lbs) 262 ± 69 248.63 ± 59.46 294.60 ± 79.93 <0.001 
Height (in) 66.31 ± 4.22 64.63 ± 3.35 70.35 ± 3.2 <0.001 
BMI 41.8 ± 10 41.7 ± 9 41.7 ± 11 0.967 
Race  
    Caucasian  
    African 
    African-American 
    Other 
    Unknown 
65% 
1% 
2% 
7% 
26% 
 
65% 
0% 
2% 
7% 
26% 
 
67% 
2% 
2% 
6% 
23% 
 
0.615 
Bariatric Surgery 
History 
     Yes 
 
 
17% 
 
 
22% 
 
 
3% 
 
 
<0.001 
BP 
    Diastolic 
    Systolic 
 
77.18 ± 10.96 
129.87 ± 13.89 
 
76.94 ± 11.08 
129.53 ± 13.67 
 
77.76 ± 10.72 
130.75 ± 14.52 
 
0.648 
0.595 
Relationship Status 
    Single 
    Partnered 
    Unknown 
 
51% 
41% 
8% 
 
53% 
40% 
7% 
 
46% 
43% 
11% 
 
0.407 
Socioeconomic Status 
Disabled 
      No 
     Disabled 
     Unknown 
Employed 
     Employed 
     On Disability 
     Unemployed 
     Unknown 
 
 
12% 
3% 
85% 
 
10% 
3% 
5% 
82% 
 
 
13% 
3% 
84% 
 
10% 
3% 
7% 
80% 
 
 
11% 
3% 
86% 
 
10% 
3% 
0% 
87% 
 
 
0.917 
 
 
 
0.192 
Smoking 
     Former 
     Current 
 
6% 
6% 
 
6% 
6% 
 
6% 
6% 
 
0.998 
Alcohol 
    Current Drinker 
 
5% 
 
5% 
 
6% 
 
0.446 
More Than One Visit 
    Yes 
    No 
 
45% 
55% 
 
46% 
54% 
 
43% 
57% 
 
0.721 
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Table 2: Baseline Data: Our Population vs. Excluded.  Values are mean ± SD  
 
 Our Population Excluded P Value 
N 84 135  
Sex 
    Female 
    Male 
 
57 (68%) 
27 (32%) 
 
99 (73%) 
36 (27%) 
 
0.384 
Age (years) 47 ± 13 46 ± 13 0.473 
Baseline Weight (lbs) 263 ± 74 261 ± 65 0.816 
Height (in) 67 ± 4 66 ± 4 0.342 
BMI 41 ± 9 42 ± 10 0.698 
Race  
    Caucasian  
    African 
    African-American 
    Other 
    Unknown 
 
62 (74%) 
1 (1%) 
1 (1%) 
8 (10%) 
12 (14%) 
 
81 (60%)  
0 (0%) 
3 (2%) 
7 (5%) 
44 (33%) 
 
0.020 
Bariatric Surgery History 
     Yes 
 
5 (6%) 
 
32 (24%) 
 
<0.001 
BP 
    Diastolic 
    Systolic 
 
76 ± 10 
129 ± 15 
 
79 ± 11 
131 ± 13 
 
0.005 
0.377 
Relationship Status 
    Single 
    Partnered 
    Unknown 
 
43 (51%) 
39 (46%) 
2 (3%) 
 
69 (51%) 
51 (38%) 
15 (11%) 
 
0.049 
Socioeconomic Status 
Disabled 
      No 
     Disabled 
     Unknown 
Employed 
     Employed 
     On Disability 
     Unemployed 
     Unknown 
 
 
22 (26%) 
5 (6%) 
67 (68%) 
 
14 (17%) 
5 (6%) 
8 (9%) 
57 (68%) 
 
 
5 (4%) 
1 (1%) 
129 (95%) 
 
7 (5%) 
1 (1%) 
3 (2%) 
124 (92%) 
 
 
<0.001 
 
 
 
<0.001 
Smoking 
     Former 
     Current 
 
9 (11%) 
5 (6%) 
 
5 (4%) 
8 (6%) 
 
0.233 
Alcohol 
    Current Drinker 
 
6 (7%) 
 
6 (4%) 
 
0.492 
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Table 3: Comorbidities all: 219 
 
 Frequency Percent 
SA 
    Yes 
 
44 
 
20% 
GERD 
    Yes 
 
28 
 
13% 
OA 
    Yes 
 
32 
 
15% 
CP 
    Yes 
 
88 
 
40% 
CVHD 
    Yes 
 
93 
 
43% 
HTN 
    Yes 
 
88 
 
40% 
HLIP 
    Yes 
 
65 
 
29% 
BP 
    Yes 
 
13 
 
6% 
DEP 
    Yes 
 
69 
 
32% 
DM2 
    Yes 
 
53 
 
24% 
DM1 
    Yes 
 
5 
 
2% 
HYPOT4 
    Yes 
 
19 
 
9% 
HPTH 
    Yes 
 
2 
 
1% 
PCOS 
    Yes 
 
4 
 
2% 
SD 
    Yes 
 
61 
 
28% 
SA: Sleep Apnea: GERD: Gastrointestinal Reflux Disease; OA: Osteoarthritis; CP: 
Chronic Pain; CVHD: Cardiovascular Heart Disease; HTN: Hypertension; HLIP: 
Hyperlipidemia; BP: Bipolar Disorder; DEP: Depression; DM2: Type 2 Diabetes; DM1: 
Type 1 Diabetes;  
HYPOT4: Hyperperothyroidism; HPTH: Hypothyroidism; PCOS: Polycystic Ovarian 
Syndrome; SD: Sleeping Disorders 
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Table 4: Comorbidities Our Subjects (n = 84) vs. excluded (n = 135) 
 
 Our Subjects Excluded P-value 
SA 
    Yes 
 
18 (21%) 
 
26 (19%) 
 
0.697 
GERD 
    Yes 
 
9 (11%) 
 
19 (14%) 
 
0.469 
OA 
    Yes 
 
10 (12%) 
 
22 (16%) 
 
0.371 
CP 
    Yes 
 
33 (39%) 
 
55 (41%) 
 
0.831 
CVHD 
    Yes 
 
39 (46%) 
 
54 (40%) 
 
0.349 
HTN 
    Yes 
 
35 (42%) 
 
53 (39%) 
 
0.724 
HLIP 
    Yes 
 
26 (31%) 
 
38 (28%) 
 
0.657 
BP 
    Yes 
 
5 (6%)  
 
8 (6%) 
 
0.994 
DEP 
    Yes 
 
25 (30%) 
 
44 (33%) 
 
0.661 
DM2 
    Yes 
 
26 (31%) 
 
27 (20%) 
 
0.066 
DM1 
    Yes 
 
1 (1%) 
 
4 (3%) 
 
0.393 
HYPOT4 
    Yes 
 
9 (11%) 
 
10 (7%) 
 
0.398 
HPTH 
    Yes 
 
2 (2%) 
 
0 (0%) 
 
0.072 
PCOS 
    Yes 
 
3 (4%) 
 
1 (1%) 
 
0.128 
SD 
    Yes 
 
25 (30%)  
 
36 (27%) 
 
0.619 
SA: Sleep Apnea: GERD: Gastrointestinal Reflux Disease; OA: Osteoarthritis; CP: 
Chronic Pain; CVHD: Cardiovascular Heart Disease; HTN: Hypertension; HLIP: 
Hyperlipidemia; BP: Bipolar Disorder; DEP: Depression; DM2: Type 2 Diabetes; DM1: 
Type 1 Diabetes; HYPOT4: Hyperperothyroidism; HPTH: Hypothyroidism; PCOS: 
Polycystic Ovarian Syndrome; SD: Sleeping Disorders 
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Table 5: Medication Usage – All Patients (n = 219) 
 
 Total Population  
(n = 219) 
Female 
(n = 156) 
Male 
(n = 63) 
GLP-1 Agonists 31 (14%) 19 (12%) 12 (19%) 
Insulin 24 (11%) 11 (7%) 13 (21%) 
Topiramate 63 (29%) 47 (30%) 16 (25%) 
Naltrexone 44 (20%) 34 (22%) 10 (16%) 
Phentermine 40 (18%) 30 (19%) 10 (16%) 
 
 
Table 6: Mean Weight Loss Barrier Scores – All Patients (n = 219) 
 
Category Mean SD 
Preventive Medical Eating 13.58 24.44 
Disordered Eating 40.59 24.91 
Food Insecurity 15.48 25.41 
Hunger Disorder 30.32 28.13 
Emotional Eating 65.98 46.39 
Craving and Binging 
    Binge Eating* 
    Craving Driven Eating*  
33.77 
29.50 
46.56 
24.85 
24.77 
37.62 
* Included in Craving and Binging score 
 
 
Table 7: Mean Weight Loss Barrier Scores Compared Between Males (n = 63) and 
Females (n = 156) 
 
Category Females 
Mean ± SD 
Males 
Mean ± SD 
P Value  
Preventive Medical Eating 14.26 ± 25.26 11.90 ± 22.39 0.519 
Disordered Eating 43.01 ± 25.39 34.60 ± 22.78 0.023 
Food Insecurity 16.12 ± 25.73 13.90 ± 24.71 0.560 
Hunger Disorder 29.54 ± 28.62 32.24 ± 26.99 0.521 
Emotional Eating 72.44 ± 43.73 50.00 ± 49.19 0.001 
Craving and Binging 
    Binge Eating* 
    Craving Driven Eating* 
36.60 ± 24.78 
31.60 ± 25.41 
51.58 ± 36.87 
26.76 ± 23.79 
24.30 ± 22.45 
34.13 ± 36.84 
0.008 
0.048 
0.002 
* Included in Craving and Binging score 
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Table 8: Mean Weight Loss Barrier Scores – Excluded (n = 135) 
 
Category Mean SD 
Preventive Medical Eating 14.07  25.48 
Disordered Eating 42.89 25.68 
Food Insecurity 18.72 27.70 
Hunger Disorder 29.95 28.91 
Emotional Eating 66.30 46.05 
Craving and Binging 
    Binge Eating* 
    Craving Driven Eating*  
33.44 
29.17 
46.48 
25.86 
25.84 
38.17 
* Included in Craving and Binging score 
 
 
Table 9: Mean Weight Loss Barrier Scores Compared Between Males (n = 36) and 
Females (n = 99) – Excluded. 
 
Category Females 
Mean ± SD 
Males 
Mean ± SD 
P Value  
Preventive Medical Eating 14.39 ± 26.99 13.19 ± 21.12 0.810 
Disordered Eating 44.95 ± 26.04 37.22 ± 24.10 0.123 
Food Insecurity 19.69 ± 28.26 16.06 ± 26.31 0.503 
Hunger Disorder 28.89 ± 28.48 32.86 ± 30.28 0.482 
Emotional Eating 72.22 ± 43.58 50.00 ± 49.28 0.013 
Craving and Binging 
    Binge Eating* 
    Craving Driven Eating* 
36.21 ± 26.22 
31.05 ± 26.75 
52.02 ± 37.40 
25.83 ± 23.53 
24.00 ± 22.71 
31.25 ± 36.54 
0.039 
0.162 
0.005 
* Included in Craving and Binging score 
 
 
